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Abstract 
 
Assessing type 2 Diabetes Associated NeuroCognitive impairment 
using an e-screening tool in a South African population 
Kirsty Bobrow; MMed (Public Health) 
University of Cape Town 
Supervisor: Virginia Zweigenthal 
Background: Type 2 diabetes has been found to be associated with cognitive impairments in 
planning, problem solving, organization, and working memory and also with an increased risk of 
dementia. Neurocognitive impairment may impact self-care and other health behaviours increasing 
the risk of poor health outcomes in this patient population. Detection of neurocognitive impairment in 
low and middle-income settings is challenging; there is a lack of validated screening tools suitable for 
local use in primary care and outpatient settings and access to formal neuropsychological testing 
services is limited. The inability to easily identify people with type 2 diabetes with neurocognitive 
impairments is constraining the development of context appropriate interventions to improve the care 
and outcomes in this sub-group of patients.  
Aim: The aim of the current analysis is to explore associations between neurocognitive function and 
measures of diabetes control (HbA1c, disease duration, type of blood glucose lowering treatment) at 
baseline in a population of people with type 2 diabetes participating in a clinical trial of treatment 
adherence support using SMS-text messages. 
 
Materials and Methods: SMS supporting treatment Adherence foR for type 2 Diabetes (StAR2D) is a 
randomised clinical trial testing if a system of SMS-text messages to support treatment adherence is 
more effective than usual care for controlling blood sugar among people with type 2 diabetes in sub-
Sahara Africa (ISRCTN70768808). We have embedded neurocognitive assessment sub-studies into 
the Cape Town trial site. At baseline participants in the StAR2D trial complete a novel mobile-device 
based cognitive assessment, NeuroScreen, assisted by a field research assistant. The assessment 
contains 9 variants of tests found in the gold-standard neuropsychological test battery that have been 
adapted and normed for use in South Africa. It is available in English or isiXhosa. The assessment 
takes between 20 to 40 minutes depending on participant error rate. This cross-sectional analysis of 
baseline data uses linear and logistic regression models to explore associations between 
neurocognitive function and measures of diabetes control. 
 
Results: Six hundred participants eligible for enrolment in the StAR2D trial were recruited from the 
Cape Town trial site; 499 participants completed the baseline neurocognitive screening assessment 
(20 to 40 minutes to complete); 101 participants did not complete the assessment (commonly due to 
eyesight, hearing or motor difficulties e.g. hemiplegia due to previous stroke or technical difficulties.) 
We found differences in the scores in some but not all the neuropsychological tests. Using cut points 
suggested by an earlier validation study of NeuroScreen tool more than half of study participants 
would be scored as having at least mild neurocognitive impairment. HbA1c, duration of disease, type 
of blood glucose lowering treatment were not significantly associated with individual or overall 
neuropsychological test scores or odds of neurocognitive impairment. 
 
Conclusions: The prevalence of neurocognitive impairment may be substantial in this patient 
population. A novel tablet based neurocognitive screening tool was broadly feasible and acceptable to 
lay researchers and trial participants. There was no evidence that HbA1c, duration of disease, or type 
of blood glucose lowering treatment (oral agents alone or insulin containing regimens) was 
significantly associated with individual or overall neuropsychological test scores or odds of 
neurocognitive impairment. Validating this tool for this patient population and optimising its role in 
routine clinical care need further study. 
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Note on structure of this thesis 
This thesis is divided in to four parts as instructed in the University of Cape Town MMed 
(minor dissertation) guidelines for Public Health Medicine. Part A is the research protocol as 
approved by the Departmental Research Committee and Faculty Research Ethics 
Committee. The research protocol describes two sub-studies. For the purposes of this 
dissertation I report on the baseline analysis from sub-study 2 only. Part B is a structured 
review of the literature; Part C presents the results of the baseline analysis from sub-study 2: 
Pilot cohort study to explore the prevalence of and associations with neurocognitive 
impairment among adults with type 2 diabetes in primary care. Part D contains the official 
ethics approval letter from the Faculty Research Ethics Committee, the author guidelines for 
PLOS and for ease of reference a copy of the multimedia appendix from Robbins et al, (1) A 
Mobile App to Screen for Neurocognitive Impairment: Preliminary Validation of NeuroScreen 
Among HIV-Infected South African Adults for a complete description of each test used in the 
assessment. 
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Background 
Type 2 diabetes is major global public health concern. (2) Low- and middle-income countries 
are disproportionally affected by the substantial and growing burden of premature morbidity 
and mortality associated with chronically elevated blood glucose levels. (3,4)  For example, 
in South Africa the estimated prevalence of type 2 diabetes is about 9%; the condition is also 
a top 10 cause of premature mortality and morbidity. (5,6) 
A key component of health care for people with diabetes is self-care and management. (6) 
Most people with type 2 diabetes will require the use of one of more blood glucose lowering 
agent in addition to a package of lifestyle modifications across many domains which often 
require ongoing negotiation in their daily lives. Planning, problem solving, organization, and 
working memory are just some of the higher order cognitive functions required for adequate 
self-care. (7) Self-care activities have been shown to be associated with improved treatment 
adherence, blood glucose control, and disease outcomes in people with type 2 diabetes. (8)  
Type 2 diabetes is a multi-system disease. Well known are the increase in risk of cardio- and 
cerebrovascular events, impaired renal function, and peripheral neuropathies and 
association with long term blood glucose control. Increasingly results from epidemiological 
research shows that type 2 diabetes may also be associated with neurocognitive impairment 
(NCI) (impairments in motor function, verbal memory, executive function, visual memory, 
processing speed, and attention and concentration) and an increased risk of dementia. (9–
13) Vascular, metabolic, and neuroendocrine factors have all been shown to contribute to 
type 2 diabetes associated NCI. (14) Epidemiological studies suggest that NCI may be a 
potential cause and consequence of variable blood glucose control. (15) Such findings 
suggest that NCI and abnormal blood glucose levels (high or low) may act in concert to 
increase the risk of poor long-term outcomes associated with the condition.   
Detection and management of NCI among people with type 2 diabetes in low and middle-
income settings is challenging. In high income settings there is generally wider availability of 
skilled professionals and validated tools to screen for NCI in people with diabetes and other 
chronic conditions. In lower income settings to formal neuropsychological testing services is 
limited. There is also a lack of validated screening tools suitable for local use to screen for 
NCI. As a result, to date little research has been done in low and middle-income countries to 
describe the burden of NCI among people with type 2 diabetes, and its association with long 
term blood glucose control and treatment adherence.  
In high income settings screening tools such as the Montreal Cognitive Assessment (MoCA) 
have been used to identify patients with type 2 diabetes and NCI and who may benefit from 
additional treatment support. (16) In these settings such support is often made available 
through interventions in the formal health care system with specialist diabetes care 
providers. (6) In low- and middle-income settings support for people with type 2 diabetes is 
based more on a volunteer-based peer support model with care provided by generalist 
health care providers. (15) The inability to easily identify people with type 2 diabetes needing 
additional support as a result of NCI in lower income settings has constrained the 
development of context appropriate interventions to improve the care and outcomes among 
this subset of patients.   
New developments in computerised neuropsychological testing combined with mobile 
communications technology have potential to improve the detection of NCI in people with 
type 2 diabetes that is scalable, low-cost and suitable to be used by non-specialist health 
care workers. (17)  Mobile devices are already being used to deliver brief messaging and 
other interventions to health care providers and individuals to support treatment adherence 
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in people with chronic conditions including type 2 diabetes in low and middle-income 
settings. (17–19) 
NeuroScreen is a tablet based health application that has been validated to screen for 
neurocognitive impairment in people living with HIV.(20) This simple tool which can be used 
by lay health workers has the potential to be an important screening tool for a range of 
chronic conditions which may be associated with neurocognitive impairment. Validation 
studies are required to validate this tool in different patient populations, and to assess the 
relative contribution of conditions in patients with multi-morbidity.  
We are proposing to, (1) validate NeuroScreen comparing it to a gold standard battery of 
neurocognitive tests, and (2) assess the burden and severity of neurocognitive dysfunction in 
a population of people with type 2 diabetes within an existing study; the SMS supporting 
treatment Adherence foR people with type 2 diabetes (StAR2D) trial.  
StAR2D is a pragmatic individual randomised trial testing whether treatment adherence 
support delivered by SMS-text message is more effective than usual care for controlling 
blood sugar among people with type 2 diabetes in diverse operational settings in sub-Sahara 
Africa. The trial will recruit participants from a general adult population of people with type 2 
diabetes receiving primary care from outpatient facilities in Cape Town, Johannesburg, and 
Lilongwe. The main trial offers an established platform for methodological advances in 
measurement tools, and exploration of further factors which may influence treatment 
adherence.  
Study aim and objectives 
The overall aim of this project is to improve the assessment of neurocognitive function in 
people with diabetes at a wide-scale to (1) validate NeuroScreen, a tablet based 
neurocognitive screening tool for use in people with type 2 diabetes, and (2) to assess the 
burden and severity of NCI in a population of people with type 2 diabetes, and (3) identify 
potential interventions to assist those with NCI in their self-care and management.  
This will be achieved through the following specific objectives:  
• Test the sensitivity and specificity of NeuroScreen to detect NCI in people with type 2 
diabetes compared to a gold standard battery of neurocognitive tests. 
• Explore the association between NeuroScreen results at baseline and 12-month 
follow-up and biological markers of blood glucose control and measures of treatment 
adherence. 
• Use sub-group analysis of main trail results stratified by neurocognitive function to 
explore differences in response to the trial intervention and to generate hypotheses 
about potential future interventions in this sub-group of people 
Study design 
 
Parent Study 
StAR2D is a pragmatic individual randomised trial testing if a system of SMS-text 
messages to support treatment adherence is more effective than usual care for controlling 
blood sugar among people with type 2 diabetes in diverse operational settings in sub-Sahara 
Africa. The specific trial objectives are to; evaluate the effectiveness of SMS messages in 
improving overall diabetes control and supporting adherence to diabetes medicines 
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compared with usual care, determine the factors (including individual, health system and 
broader contextual factors) influencing the intervention impact as well as uptake, 
maintenance, scaling-up  and potential for long-term engagement with the technology using 
both quantitative and qualitative methods, and to examine the incremental  cost and 
cost-effect iveness of introducing a new SMS-text messaging programme into an 
existing health service setting. The trial will recruit participants from a general adult 
population of people with type 2 diabetes receiving primary care from outpatient facilities in 
Cape Town, Johannesburg, and Lilongwe. 
We propose leveraging the platform of the main trial for a set of sub-studies at the Cape 
Town site to validate NeuroScreen and to assess the burden and severity of neurocognitive 
dysfunction in people with type 2 diabetes. 
Sub-study 1: Validation of NeuroScreen to detect NCI in people with type 2 
diabetes 
The aim of this cross-sectional study component is to assess sensitivity and 
specificity for NeuroScreen in adult patients with type 2 diabetes managed in primary care.  
Participants 
Inclusion and exclusion criteria 
Enrolled in the StAR2D trial and willing and able to provide consent to participate in this sub-
study. StAR2D inclusion and exclusion criteria apply,  
   Inclusion Criteria 
• Participant is willing and able to give informed consent for participation in the study. 
• Able to communicate in one of the predominant indigenous African languages in the 
South African provinces (e.g. English, Afrikaans Xhosa, Zulu and Sesotho), and in 
Malawi, the Chichewa language 
• Male or female, aged 18 years or above. 
• A diagnosis of type 2 diabetes. 
• Taking oral glucose lowering treatment  
• Has access to a cell-phone  
• Knows how to use SMS (it is okay if participant needs help to send or retrieve SMS) 
• Currently lives in the community served by the clinic and plans to live there for the 
next 18 months 
Exclusion Criteria 
The participant may not enter the study if ANY of the following apply: 
• Within three months of a hospital admission for hyperglycaemia or hypoglycaemia 
• Pregnant or within three months post-partum by self-report or with plans to become 
pregnant in the next 12-months 
• A terminal medical condition 
• Another member of the household already recruited to the trial 
• Participation in the formative work for the intervention 
In addition to the StAR2D exclusions participants who self-report the presence of a current 
psychotic disorder, significant current suicidal ideation, and or recent hospital admission for 
hypoglycaemia will be excluded from participation in the validation sub- study. Trial 
participants who do not know their HIV status will be excluded from the validation study. Trial 
participants who self-report a head injury that has led to more than 30 minute loss of 
consciousness or overnight hospitalisation, previous central nervous system disorders, for 
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example stroke and epilepsy, depression and substance abuse disorders will also be 
excluded from the validation sub-study. 
Setting 
Participants will be recruited from the main StAR2D trial site at Vanguard Community Health 
Centre, Cape Town, South Africa. NeuroScreen will be administered at this site. Formal 
neuropsychologocal testing will be done at the Department of Psychiatry and Mental Health 
at Groote Schuur Hospital. 
Measurements 
NeuroScreen 
NeuroScreen is a tablet-based neurocognitive screen that consists of 9 
neuropsychological tests. These types of tests are sensitive to the NCI associated with type 
2 diabetes - learning, memory, executive functioning, attention/concentration, processing 
speed, and motor functioning. (14) All the neuropsychological tests embedded in the app are 
novel variants of those found in the gold-standard neuropsychological test battery that have 
been adapted and normed for use in South Africa for English or isiXhosa speakers (see 
“Gold-Standard Neuropsychological Battery” below).  Raw scores from each test will be 
totalled and transformed into Z-scores based on the full sample results.   
 
Standard Comparator  
The Gold-Standard Neuropsychological Test Battery is a paper-and-pencil test 
battery that assesses individuals across seven cognitive domains using tests that have been 
shown to be sensitive with NCI seen in type 2 diabetes: learning and memory (Hopkins 
Verbal Learning Test-Revised and the Brief Visuospatial Memory Test-Revised); executive 
functioning (Color Trails Test 2, Stroop Color Word Test, and the Wisconsin Card-Sorting 
Test); attention/concentration (Mental Alteration, Mental Control and Digit Span); processing 
speed (Trail Making Test, Part A, and Digit Symbol Coding); language (semantic fluency of 
animals, fruits and vegetables), and motor functioning (finger tapping and grooved 
pegboard.) (14,16)  This particular paper-and-pencil battery has been used by the UCT team 
for several other studies, and has been normed and validated for use with isiXhosa-
speakers. (21,22) Data will include (1) raw test scores, (2) scaled scores; (3) age, education, 
gender and/or language adjusted T-scores; (4) individual domain deficit scores; and (5) 
global deficit scores.  Demographic information (e.g., age and education) will be available 
from the StAR2D trial and will be controlled for in the predictive model (see Statistical 
Analysis below).    
Procedures 
Recruitment 
After StAR2D assessment is completed participants who meet study criteria for the 
validation arm will be invited to participate in the sub-study. They will be given a study 
information sheet and time to consider whether they wish to participate. If they decide to 
participate a booking will be made for them to have the gold-standard battery of 
neuropsychiatric tests performed at Groote Schuur Hospital within two weeks of completing 
the NeuroScreen assessment. 
Informed consent 
The parent study informed consent process includes the NeuroScreen assessment at 
baseline and 12-month follow-up Informed consent procedures in the parent study (StAR2D) 
include completing the NeuroScreen at baseline and 12-month follow-up. Participants will 
consent for the parent study (StAR2D) and those participants who are eligible and willing to 
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participate in the enrolled in the validation study will provide additional written informed 
consent. Participant information leaflets and informed consent procedures will conform to the 
Helsinki Declaration and local HREC requirements. 
Study procedures 
The NeuroScreen questionnaire will be added to the baseline assessment of StAR2D 
trial patients enrolled at the Cape Town site. Trained psychometrists will administer and 
score the gold-standard battery, and enter the data into the database, within 7 days of the 
NeuroScreen assessment.  Participants and lay health care workers will also be asked to 
complete a short survey on the acceptability of the NeuroScreen questionnaire. At the end of 
the formal assessment a per diem which may include money for transport costs will be 
provided to the participant.   
Dr. Gouse, a neuropsychologist, will review the results of the Gold Standard Battery and 
calculate the global deficit score (GDS) for each patient, and we will use this GDS to identify 
those who have impairment and those who do not.  The GDS is a robust method of 
summarizing neuropsychological battery scores to determine presence and severity of 
neurocognitive impairment.(23) Individual test T-scores are converted to a deficit score from 
0 (no impairment) to 5 (severe impairment); deficit scores are averaged across all tests to 
create the GDS.  The GDS considers number and severity of impairments, assigning less 
weight to unimpaired performance and overcoming the disadvantage of averaging absolute 
performance, which gives equal weight to unimpaired and impaired scores. (9,13,24) The 
GDS method detects mild NCI (GDS≥0.5) across varying impairment patterns in different 
neurocognitive domains. (9,13,23,25) We will set the threshold of GDS ≥ 0.5 as indicative of 
NCI.  
Statistical Analysis 
We will review the data for each variable we will explore graphically and formally test 
normal distribution assumptions. 
We will compute the sensitivity (i.e., proportion of participants with impairment, 
among those who satisfied the criterion) and specificity (i.e., proportion of participants 
without impairment, among those who did not satisfy the criterion) of the NeuroScreen tool. 
Positive and Negative predictive values will also be calculated to truly define those with or 
without impairment. The area under the curve and the goodness of fit for the data will be 
assessed via the Receiver Operator Curve and the C-statistic respectively while considering 
the set threshold pf GDS≥0.5.  
To assess the validity of the NeuroScreen tool we will calculate the sensitivity and specificity, 
positive and negative predictive values, the area under the receiver operating characteristic 
(AUC) curve and C-statistic as compared to GDS ≥ 0.5. (26,27) Using the strategy 
suggested by Bland and Altman we will enrol 100 participants in the validation sub-study. 
(26)  
Sub-study 2: Pilot cohort study to explore the prevalence of and associations 
with NCI among adults with type 2 diabetes in primary care 
The aim of this component is to explore associations between neurocognitive 
function and blood glucose control and treatment adherence, and to explore change in score 
over time. 
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Participants 
Inclusion and exclusion criteria 
All participants enrolled in the StAR2D trial recruited from the Cape Town site. StAR2D 
inclusion and exclusion criteria apply, After StAR2D enrolment and baseline assessment is 
 Inclusion Criteria 
• Participant is willing and able to give informed consent for participation in the study. 
• Able to communicate in one of the predominant indigenous African languages in the 
South African provinces (e.g. English, Afrikaans Xhosa, Zulu and Sesotho), and in 
Malawi, the Chichewa language 
• Male or female, aged 18 years or above. 
• A diagnosis of type 2 diabetes. 
• Taking oral glucose lowering treatment  
• Has access to a cell-phone  
• Knows how to use SMS (it is okay if participant needs help to send or retrieve SMS) 
• Currently lives in the community served by the clinic and plans to live there for the 
next 18 months 
Exclusion Criteria 
The participant may not enter the study if ANY of the following apply: 
• Within three months of a hospital admission for hyperglycaemia or hypoglycaemia 
• Pregnant or within three months post-partum by self-report or with plans to become 
pregnant in the next 12-months 
• A terminal medical condition 
• Another member of the household already recruited to the trial 
• Participation in the formative work for the intervention 
Setting 
Participants in this sub-study are a sample of participants from the main StAR2D trial from 
the Cape Town site, Vanguard Community Health Centre. The NeuroScreen questionnaire 
will be part of the baseline and follow-up assessment for all trial participants recruited at the 
Cape Town site. 
Measurements 
The NeuroScreen mobile-device based questionnaire consists of 10 tests sensitive to the 
NCI associated with type 2 diabetes: learning, delayed recall (memory), executive 
functioning, attention/concentration, processing speed, and motor functioning. (14)  
Procedures 
Recruitment 
The NeuroScreen questionnaire questionnaire will be part of the baseline and follow-
up assessment for all StAR2D trial participants recruited at the Cape Town site. 
Informed consent 
Participants provide written informed consent to participate in the parent study 
(StAR2D.)   Participant information leaflets and informed consent procedures will conform to 
the Helsinki Declaration and local HREC requirements. 
Study procedures 
StAR2D participants have the NeuroScreen questionnaire administered as part of 
their baseline and final follow-up assessments for the trial. This sub-study will leverage the 
infrastructure, participant pool, and biomedical and behavioural outcome data of the StAR2D 
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trial in Cape Town (Vanguard Community Health Centre.)  Demographic, medical (including 
HbA1c, lipid profile and blood pressure), and adherence data are collected at baseline (pre-
intervention), and at 12 months follow-up in the StAR2D trial. 
Statistical Analysis 
We will review the data for each variable we will explore graphically and formally test 
normal distribution assumptions. We will conduct cohort analyses exploring for associations 
between baseline blood glucose control and NCI at 12-months controlling for various factors; 
exploratory analysis of change in NCI score between baseline and 12-months by blood 
glucose level.  
The prevalence of cognitive impairment in adults with diabetes ranges from 2.2% in a 
population of people newly diagnosed with diabetes (in outpatient care) to 26.1% in a 
population based survey of adults older than 65 years. (11,28) In a small local study of a 
specialist hospital in-patient population of people with diabetes found a prevalence of 52%. 
(29) Prevalence could be lower or higher depending on the proportion of the sample with 
recently diagnosed diabetes, level of blood glucose of control, and co-morbid conditions. 
Thus if we assume a prevalence of this outcome to be about 32% then our sample size is 
sufficient to detect the prevalence of cognitive impairment as low as 26% and as high as 
35% with 80% power at 5% significance.   
Risks and benefits 
Although participating in the study is low risk participants may feel distressed if they perceive 
their neurocognitive functioning is poor. Participants may also disclose substance use or 
mental health issues that necessitate referral. Participants in the validation study may 
experience distress at the idea of being ‘tested’ and may perceive the tests to indicate 
intelligence rather than function. In addition, the formal gold-standard battery of tests takes 
about 2 hours and this may result in mental fatigue for the participants.  
Participants in the StAR2D trial will not be incentivised for their participation in the text 
message programme. Where additional travel to clinics may be required, they will be offered 
reimbursement of travel costs and provide an incentive that will cover the cost of a small 
meal. Eligible participants who decide to participate in the validation sub-study will also be 
offered reimbursement of travel costs for additional visit for the neuropsychological 
evaluation at the hospital and an incentive to compensate for time for the neuropsychological 
evaluation and lost earning potential.  
Privacy and confidentiality 
Data collected as part of this study will conform to the requirements and standards of the 
parent study. Please see the StAR2D data management plan. 
Discontinuation/Withdrawal of Participants from Study 
Participants who withdraw from the StAR2D trial will automatically be withdrawn from the 
DANCes sub-study. In addition participants in the main trial who withdraw from the validation 
study will continue to participate in the StAR2D trial without any effect on their participation, 
follow-up or standards of clinical care they receive.  
What happens at the end of the study? 
The end of the study is defined as the end of the final interview with the trial participant. 
When data analysis is complete, the findings will be shared as per the StAR2D reporting 
requirements. 
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Quality assurance procedures 
The study may be monitored, or audited in accordance with the current approved protocol, 
GCP, relevant regulations and standard operating procedures. 
Ethical and regulatory considerations 
Declaration of Helsinki 
The Investigator will ensure that this study is conducted in accordance with the principles of 
the Declaration of Helsinki.  
 
Guidelines for Good Clinical Practice 
The Investigator will ensure that this study is conducted in accordance with relevant 
regulations and with Good Clinical Practice. 
 
Approvals 
The protocol, informed consent form, participant information sheet and any proposed 
advertising material will be submitted to an appropriate Research Ethics Committee (REC), 
and host institution(s) for written approval. 
The Investigator will submit and, where necessary, obtain approval from the above parties 
for all substantial amendments to the original approved documents. 
Reporting 
The CI shall submit once a year throughout the study, or on request, an Annual Progress 
report to the REC Committee, host organisation and Sponsor.  In addition, an End of Study 
notification and final report will be submitted to the same parties. 
 
Participant Confidentiality 
The study staff will ensure that the participants’ anonymity is maintained.  The participants 
will be identified only by a participant ID number on all study documents and any electronic 
database, with the exception of the CRF, where participant initials may be added.  All 
documents will be stored securely and only accessible by study staff and authorised 
personnel. The study will comply with the Data Protection Act, which requires data to be 
anonymised as soon as it is practical to do so. 
Finance and insurance 
Funding 
This study is self-funded through the CDIA network. 
Publication policy 
The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press 
releases and any other publications arising from the study.  Authorship will be determined in 
accordance with the ICMJE guidelines and other contributors will be acknowledged. 
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Appendix1. Copy of participant information leaflet and informed consent 
form for sub-study 1 
 
PARTICIPANT INFORMATION LEAFLET AND 
CONSENT FORM 
TITLE OF THE MAIN RESEARCH PROJECT: SMS supporting treatment Adherence foR 
for type 2 Diabetes (StAR2D) 
TITLE OF SUB-STUDY:  Assessing type 2 Diabetes Associated NeuroCognitive 
impairment using an e-screening tool in a South African population 
PRINCIPAL INVESTIGATOR: Professor Naomi Levitt (Dr Kirsten Bobrow – clinical 
coordinator) 
ADDRESS: Chronic Diseases Initiative for Africa (CDIA) J-47, J-floor, Old Main 
Building Groote Schuur Hospital,  Observatory 7925  Cape Town. Tel: +27 21 406 6140 
You have entered the StAR2D study and have just completed your last study visit for it. We 
would like to invite you to take part in another linked study.  Please take some time to read 
over the information about this new study.  You do not have to enter this new study – it is 
your choice whether you want to or not. Your participation is entirely voluntary. If you say 
no, this will not affect you negatively in any way.  It will not affect your participation in the 
StAR2D study or services you are receiving at this clinic.  You are also free to withdraw from 
the study at any point, even if you do agree to take part.  
If you have any questions or are confused about anything, please ask the study staff or 
doctor any questions about any part of this new study that you do not fully understand.  It is 
very important that you feel fully satisfied in your understanding of what participating in this 
study requires.  
This study has been approved by the Human Research Ethics Committee of the Faculty 
of Health Sciences of the University of Cape Town (UCT HREC 820/2016).  This study 
will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
➢ People living with type 2 diabetes often experience memory, thinking, attention, and 
concentration problems, as well as problems with coordination (known as cognitive 
problems). These problems can interfere with daily life and put individuals at risk for 
developing more severe cognitive problems. 
➢ Knowing if people are experiencing cognitive problems is challenging, and a new tool 
that can be used by health care workers has been developed to help screen for 
cognitive problems among people living with type 2 diabetes. 
➢ This study will be conducted at the study site to see how well the new tool can detect 
cognitive problems compared to the original tests. The study will include up to 100 
participants who have completed the StAR2D study.  
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➢ In this study, you will be asked to complete a brief assessment of your mental health 
and a neuropsychological test battery that will take 2-3 hours. The 
neuropsychological battery will also ask you to remember things, drawing lines with 
your finger, and do other game-like activities that will assess your cognitive abilities. 
You will be able to complete this on the same day as you complete your StAR2D 
visit, or within 7 days of the visit.   
➢ The study will not offer special treatment or medication.  You will be provided with 
transport to the study site, a meal, and a small stipend when attend your visit. 
 
What will your responsibilities be? 
➢ If you agree to take part in this study, you will sign this form.   
➢ You will be administered a short series of neuropsychological tests on a smartphone, 
which consist of remembering some words, tapping buttons on a smartphone, 
repeating number sequences, and using your finger or a stylus to connect dots on 
the smartphone screen. 
➢ Then, the study counsellor will administer the screening tool on the tablet to you, 
which consists of remembering some words, tapping buttons, repeating number 
sequences, and using your finger to connect dots on the tablet screen. 
➢ You will also be asked to answer some questions about your experience using 
computers and mobile deceives, and what it was like to use the tablet device.  
➢ Then, you will be asked to complete the longer assessment that will take 2-3 hours. 
You can complete it today or come back within 7 days to complete it.  
➢ The longer assessment will ask you questions about how you’ve been feeling in the 
past month, and ask you to remember things, draw, tap your finger, put pegs in 
holes, repeat number sequences, and solve problems. 
➢ Your name will not be attached to any of the forms and results: they will only be 
identified with a study identification number.  
➢ As part of this research project, the researchers will collect your unique StAR2D 
study number and  get the following information from your StAR2D research record: 
your demographic information (age, gender, race, ethnicity, years of education, 
handedness), information about your diabetes medications, medical information, 
such as your HbA1C levels. All other information (your age, whether you are male or 
female, date of birth, whether you are taking medicines, the measurements made by 
the blood pressure machines and the blood test results) will not have your name on, 
and will just have a code so that the results could not be linked back to you.  
Will you benefit from taking part in this research? 
➢ You will not personally benefit from participating in this new study.  Participation 
could possibly help researchers and scientists understand if the new screening tool 
works accurately, and this could lead to improved health for people like you. 
 
Are there any risks involved in your taking part in this research? 
➢ During the testing, you may experience emotional upset, embarrassment, or 
discomfort.  If you request it and if you agree, the tests and interview will be stopped 
and rescheduled. Referral to appropriate counselling or support services can be 
made if you wish.   
➢ There always exists the potential for loss of private information; however, there are 
procedures in place to minimize this risk.   
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If you do not agree to take part, what alternatives do you have? 
➢ Participation in the study is voluntary. You may withdraw from the study at any time. 
There are no alternatives to participation.  You are free not to participate or to 
withdraw at any time during the study.  Your treatment will not be affected in any 
way, nor will your participation in the StAr2D study.  You may continue to attend your 
clinic. It would be helpful for the study team to let us know why you have decided not 
to take part, but you are free to not give a reason. 
Can you be dismissed from the study for any reason? 
➢ Once you begin study participation, study staff may ask you to leave the study before 
you complete it.  This is rare.  There are several reasons this could happen such as 
becoming so medically or mentally sick you cannot attend study visit.  If this 
happens, the study staff will refer you to appropriate health services.  If you get better 
and wish to continue in the study, you may contact the study staff. 
What if you decide you no longer want to participate in the study? 
➢ Your participation is completely voluntary.  You may withdraw from the study at any 
time.  If you do, you will not lose any benefits to which you are otherwise entitled.  
Withdrawal will not affect the services provided to you by the clinic. 
Who will have access to your medical records? 
➢ The information collected about you will be treated as confidential and protected.  If 
we write about this work, we will not identify you personally.  Only the research study 
team will have full access to the information. Other researchers may have access to 
this data only in a securely anonymised form. Information you provide may be stored 
by the project team for a period of time after the project ends. Any personal 
information about you will be destroyed at the end of the study. 
Is the information you provide confidential? 
➢ All research study staff are instructed to keep all of your study information secret.  
They are not allowed to discuss it with the clinic staff.  They are only allowed to 
discuss it with the research study staff. All study information will be identified by 
unique ID numbers and will be kept in locked file drawers.  These records will only be 
available to research study staff.  Institutional personnel may access it as part of 
routine audits.  A list matching participant names with ID numbers will be kept in a 
separate locked file drawer.  This information will only be available to research study 
staff.  Study results will be reported only as a group.  This way, no individual 
participant can be identified. 
Will you be paid to take part in this study and are there any costs involved? 
➢ You will be reimbursed for your transport costs and time to complete the study 
procedures.  You will receive R200.00 when you complete all of the study questions 
and evaluations for the validation sub-study. 
➢ The maximum compensation is R200.00. 
 
What if you get injured as a direct result of participating in this study? 
➢ Free essential medical treatment is available to you only if you are injured because of 
your participation in this study.  You will not receive any money as compensation for 
injury. 
 
 
 
 
Part B draft 1  29/03/2018 
30 
 
In case of an emergency or if you feel you need to contact one of the study doctors, 
you can do so by phoning  
Professor Naomi Levitt or Dr Kirsten Bobrow at tel no 021-6505351 
 
➢ You can also contact the Human Research Ethics Committee of the Health Sciences 
Faculty of the University of Cape Town 021-4066338 if you have any concerns or 
complaints that have not been adequately addressed by study staff. 
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Information and Consent Summary 
 
Ensure that each participant clearly understands each of the following points: 
➢ You are being asked to partake in a research study linked to the StAR2D study 
because you already in the StAR2D study.  
➢ As a participant in the study, you have already completed the NeuroScreen on a 
tablet device, at one study visit at the field site, you will: 
 Allow the study psychometrist to administer a comprehensive neuropsychological 
battery to you. 
➢ Everything you share during the visits is confidential. Only those people involved in 
this research study will see your answers to the questions. The clinic staff will not 
have access to your answers. 
➢ Your participation in this study is completely voluntary. 
➢ Your participation or decision not to participate in the study WILL NOT affect your 
care at the clinic. 
➢ You can withdraw from the study at any time without negative consequences and you 
can continue receiving care at this clinic. 
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DECLARATION BY PARTICIPANT 
 
PARTICIPATION IN RESEARCH STUDY 
 
By signing below, I ______________________________ agree to take part in a research 
study entitled: “Assessing type II Diabetes Associated NeuroCognitive impairment using an 
e-screening tool in a South African population (DANCes); a validation study” 
I declare that: 
• I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan as 
agreed. 
 
Signed at (place) __________________________________ on (date) ______ 20____. 
 
_______________________________________________ 
Signature/Fingerprint of participant 
 
DECLARATION BY INVESTIGATOR/STUDY COORDINATOR 
 
I (name) _________________________________declare that: 
 
• I explained the information in this document to 
_________________________________ 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
Signed at (place) ____________________________ on (date) ________ 20____. 
__________________________________________________ 
Signature of investigator/study coordinator 
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Part B: Structured literature review on the 
relationship between cognitive function 
and self-care and related health 
behaviours in adults with type 2 diabetes 
mellitus 
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Introduction 
Background 
Type 2 diabetes is major global public health concern. (2) Low- and middle-income countries 
are disproportionally affected by the substantial and growing burden of premature morbidity 
and mortality associated with the condition. (3,4)  In South Africa the estimated prevalence 
of type 2 diabetes is about 9% and  it is a top 10 cause of premature mortality and morbidity. 
(5,6) 
Type 2 diabetes is a progressive multi-system disease. Published results from 
epidemiological studies suggest that type 2 diabetes may also be associated with and 
increased risk of neurocognitive impairment and dementia. (14,30,31) Well known are the 
increase in risk of cardio- and cerebrovascular events, impaired renal function, and 
peripheral neuropathies in people with type 2 diabetes and the association between event 
risk and long-term blood glucose control. (9–13)  
Although results observational epidemiological studies have consistently shown an 
association between type 2 diabetes and cognitive impairments and dementia there remains 
no unifying theory of the underlying mechanism. The neuropathological processes are likely 
multi-factorial and may occur in parallel. Vascular, metabolic, and neuroendocrine factors 
have all been shown to contribute to risk neurocognitive impairment and dementia in people 
with type 2 diabetes. (14) 
Imaging and post-mortem studies show that cortical grey matter volumes are reduced, and 
there is a high burden of vascular disease in this population.(32,33) Pre-clinical, 
pathological, and imaging studies in have shown associations between type 2 diabetes and 
disruptions in the blood-brain-barrier, neuronal insulin resistance and impaired signalling, 
abnormal mitochondrial function and a pro-inflammatory state which may increase the 
presence of abnormal proteins (like amylin) or decrease clearance of amyloid and tau. (33–
36) There is some evidence for gene-environment interactions with people who are Apoe4 
allele carriers and who have diabetes at even greater risk for dementia.(33) Finally, more 
research is needed to clarify the role of treatments including exogenous insulin in mediating 
or mitigating pathophysiological process.(10,37) 
Most people with type 2 diabetes will require the use of one of more blood glucose lowering 
agent in addition to a package of lifestyle modifications across multiple domains including 
diet and physical activity. Ongoing modification of lifestyle and adoption of diabetes related 
health behaviours (foot care, timing of medication and meals, attending clinic appointments 
on-time) is achieved through daily self-care and management activities. (38) Planning, 
problem solving, organization, and working memory are just some of the higher order 
cognitive functions required to successfully navigate these behavioural tasks. (39) Self-care 
activities have been shown to be associated with improved treatment adherence, blood 
glucose control, and disease outcomes in people with type 2 diabetes. (38,40)  
Objectives 
The objective of this structured literature review is to summarise the available published 
evidence on the nature of the relationship between cognitive function and self-care and 
related health behaviours in adults with type 2 diabetes mellitus. Attention will be given to 
identification of specific cognitive domains (and specific tests) which may be particularly 
affected in adults with type 2 diabetes, and their association with self-management and other 
health related behaviours and outcomes.  
Part B draft 1  29/03/2018 
37 
 
Methods 
A literature search was conducted in July and August 2016 and up-dated in January 2018. 
Search terms 
Search terms were grouped under the themes: type 2 diabetes, self-management and health 
behaviours, and cognitive functions and impairment. (See table 1.) 
Table 1 Search themes and terms used in to search published literature 
Primary Search Terms Key words / associated terms Information  
Type 2 diabetes mellitus Type 2 diabetes mellitus 
Self-management and health 
behaviours 
Self-management; self-care; treatment adherence 
 
Cognitive functions and 
impairment 
Diabetes; brain; cognition; cognitive; cognitive performance; executive 
function; neuropsychological test; mild cognitive impairment (MCI); cognitive 
impairment; cognitive dysfunction; risk factor; 
 
 
Data bases 
Peer-reviewed published literature from 01/01/1990 to 31/12/2017 was searched using 
search engines PubMed, Web of Science, OVID, CINHAL and the Cochrane library. 
Searches were restricted to studies in humans, no language restrictions were set.  
A hand search of references from studies included in the review was also performed. 
1.1. Inclusion and exclusion criteria 
Studies were included if,  
• Study population human adults (> 18 years of age) 
• Observational (cross sectional or longitudinal) or intervention studies 
• Contained people with type 2 diabetes (self-report, medical record review, measured 
using international guidelines for measurement and interpretation of short or long 
term blood glucose levels.) 
• Objective measure of neurocognitive function using validated and reliable tests (not 
limited to specific tests) 
• Objective measure of self-care or health behaviour (either self-care scale or one of 
the criteria from ADA statement on Self-Management and Support Education;  
diabetes pathophysiology and treatment options, healthy eating, physical activity, 
medication usage, monitoring and using patient-generated health data, preventing, 
detecting, and treating acute and chronic complications, healthy coping with 
psychosocial issues and concerns, problem solving) (38) 
 
Studies were excluded if,  
• Small studies (<100 participants with type 2 diabetes) 
• Did not report measurement of cognitive function (i.e. reported only diagnosis of 
dementia or cognitive impairment) 
• Did not report measurement of self-care or health behaviour  
• Did not control for gender 
• Did not control for age 
• Did not control for education 
• Figure 1 Flow diagram describing how studies selected for review 
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Figure 2 Flow diagram describing how studies selected for review 
 
Results 
542 records were retrieved from the various databases for title and abstract review. 54 
studies which were reviews of the literature were excluded (the bibliographies were 
searched for additional relevant studies.) Duplicates were removed as were studies which 
did not meet inclusion and exclusion criteria. Twelve studies were eligible for final review. A 
hand search of references from studies included in the review was also performed. The final 
number of studies included was fourteen.(41–54) 
Study and sample characteristics 
Tables 2a and 2b show study design, sample size and location, main study aims, and how 
type 2 diabetes was diagnosed, neuropsychological and self-management measures for the 
selected studies. Of the selected studies most were observational; cross sectional design 
(11), case control (1); cohort (3). One study used data from a cluster randomised trial. 
Sample sizes ranged from 112 participants to 27 271. No studies came from low income  
settings; fourteen studies were conducted in high income countries; one study was 
conducted in China (upper middle-income.) The primary aim of most studies was to explore 
the association between cognitive function or impairment and some measure of self-
management among adults with type 2 diabetes. In six studies it was a secondary aim or 
studies included sufficient information on neurological function testing and self-management 
to be included in the review.  
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The studies included 45 586 participants. Table 2 shows selected participant characteristics 
from the included studies. Although the mean age of participants in most of the studies (10 
of 16) was 70 years or older (in two it was over 80 years of age) the mean age of most of the 
individual participants was 62 (SD 11) years. Most of the studies enrolled more women than 
men; calculating a weighted average 63% of all the participants were women. Level of 
education was variously reported making it difficult to compare across studies. All studies 
included education in their models even if they did not present this variable in the results. 
Few studies reported the ethnicity of study participants again making it difficult to compare 
across reported. 
Diagnosis of Type 2 Diabetes and measures of glycaemia 
Studies included adults with either prevalent or screen diagnosed type 2 diabetes. Three 
studies included participants who self-reported a physician diagnosis of type 2 diabetes; 
Tran et al used self-report alone as a binary variable i.e. did not report measure of 
glycaemia.(47)  Jagielski et al used data from the Guangzhou Biobank Cohort Study (GBCS) 
self-report of physician diagnosis and use of blood glucose lowering treatments and 
measured fasting blood glucose levels; categorised as normal (<5.6 mmol/l), impaired (≥5.6–
<7.0 mmol/l), and type 2 diabetes (≥7.0 mmol/l.) They did not report the number of screen 
detected cases of type 2 diabetes.  Demakakos et al used data from the English Longitudinal 
Study of Aging (ELSA) which supplemented self-report data with biennial blood sampling for 
HbA1c levels; 90% of participants took part in the second wave of data collection which 
included blood sampling.(55,56)  The remaining studies used record reviews and laboratory 
testing of HbA1c levels.  
The studies by Tran et al and Demakakos et al used presence or absence of type 2 diabetes 
to classify study participants and did not report measures of glycaemia. In the remaining 
studies all except Rodríguez-Pascual et al and GBCS used HbA1c as a continuous measure 
of glycaemia in their models.  In Rodríguez-Pascual et al percentage HbA1c was 
summarised into a binary variable indicating metabolic control (good or not) by age1; in the 
GBCS fasting blood glucose was treated as a categorical variable (see above).(50) The 
mean weighted HbA1c for studies of people with prevalent type 2 diabetes was 7.25%. 
HbA1c results for individual studies are presented in table 3. 
Cognitive domains and neuropsychological tests  
Studies reported testing various cognitive domains using a variety of neuropsychological 
tests. (See tables 2 and 3.) Cognitive domains and tests mapped to them were not reported 
in a standardised manner. Appendix 1 contains list of cognitive domains and 
neuropsychological tests adapted from NHI Health Brain Project. Most commonly studies 
used the Mini Mental Status Exam or another combined measure of mental status with or 
without additional individual tests as a measure of cognitive function and to classify 
participants as impaired or not (9 of 15.)  Use of combined measures may lead to 
misclassification of cognitive impairment sub-types. For example, risk of dementia is known 
to be increased in people with type 2 diabetes and people with early stage disease may 
have similar MMSE scores to those with diabetes associated cognitive impairment. Of the 
studies using the MMSE only two reported excluding participants with prevalent dementia 
(49) however all studies required written informed consent making it unlikely people with 
                                                          
1 Glycosylated haemoglobin: patients without high comorbidity or associated disability ≤7% if under 80 years, 
and <8% if 80 or more years. In patients with high comorbidity or functional impairment <8% if under 80 years 
old, and <8.5% if in 80s or over.(44) 
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severe dementia would be included; participants with early stage dementia may have been 
included in the studies and may have been misclassified. 
Individual neuropsychological tests reported most commonly by the included studies were, 
RAVLT or other word recall test (n=4), Stroop (n=3), Trails A, B (n=2), Clock (n=2), Digit 
Symbol Coding or Substitution (n=2). Lack of uniform testing and reporting make it difficult to 
compare across studies. For example, three studies used mean MMSE scores (41,47,52), 
two used MMSE as a binary variable with cut point of ≤24 to indicate impairment (50,57) 
although Jagielski et al defined cognitive impairment using a Delayed Word Recall Test 
score <4 (mean = 5.36; SD = 1.42).(50) Five studies presented raw test scores, 
(44,45,53,54,58) four standardised their scores calculating t, z, or g-scores. (42,43,46,59) 
Three studies used physician review and diagnostic criteria to classify participants as 
impaired or not. (48,49,51) 
A recent systematic review explored the effect size for individual neuropsychological tests 
frequently reported in the literature on cognitive impairment in adults with type 2 diabetes. 
(14) The authors reported that the domains most commonly tested were verbal and visual 
memory, attention/concentration, processing speed, and executive function.   
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Table 2 Characteristics of observational studies included in this review 
Authors  Study Design 
(sample size) 
Location Aim of study Diabetes diagnosis Neuropsychological tests Self-help or other health 
behaviour measures 
Sinclair et al, 
2000 (41) 
Case control 
(n=789) 
UK (Wales) Explore association between cognitive 
impairment and changes in self-care 
behaviour, use of health and social 
services in adults with and without 
type 2 diabetes 
Record review or 
physician diagnosis 
Mini Mental State Exam (MMSE) 
Clock Drawing Test  
Barthel Index and the Extended 
ADL Scale 
Kazlauskaite 
et al, 2009 
(42) 
Cross 
sectional 
(n=115) 
USA Determine prevalence of inaccurate 
SMBG and predictors of inaccurate 
reporting in adults with diabetes   
Record review or 
physician diagnosis 
Digit Symbol Coding Test (DSCT) 
Rey Auditory Verbal Learning Test  
(RALT) 
Trail Making Tests A, B (TMT-A,B) 
Blood glucose self-monitoring 
(glucose diary accurate; meter with 
at least 10 readings in past 60 
days) 
Primozic et 
al, 2010 (43) 
Cross 
sectional 
(n=114) 
Slovenia Explore association between cognition 
and emotion self-management in 
patients with type 2 diabetes 
Record Review or 
physician diagnosis 
Repeatable Battery for the 
Assessment of Neuropsychological 
Status (RBANS) 
Tower of London (ToL)  
Stroop Colour and Word Test  
Diabetes Self-Care Activities 
(SDSCA) measure 
Rodríguez-
Pascual et al, 
2011 (44) 
Cross 
sectional 
(n=112) 
Spain To describe characteristics, level of 
metabolic control, and health related 
quality of life in older people with type 
2 diabetes 
Record Review or 
physician diagnosis 
Pfeiffer abbreviated questionnaire EuroQol 5-Dimensions (EQ-5D) 
Red Cross 
ADLS 
IADLS 
Feil et al, 
2012 (45) 
Cross 
sectional 
(n=1 398) 
USA To examine relationships between 
cognitive impairment and diabetes 
self-care ability  
Laboratory 
(HbA1c) 
Telephone Interview for Cognitive 
Status (modelled after MMSE) 
Taking diabetes medication, 
exercising regularly; following a 
recommended eating plan; 
checking blood glucose level; and 
checking feet for wounds or sores. 
Munshi et al 
2012 (46) 
Cross 
sectional 
(n=145) 
USA Association between executive 
function variously measured with 
glycaemic control in type 2 diabetes 
Record Review or 
physician 
Clock-in-a-box 
Phonemic verbal fluence 
Trails A,B 
Dysexecutive questionnaire; 
Activities of Daily Living (ADLS); 
Instrumental Activities of Daily 
Living (IADLS); Falls 
Tran et al, 
2014 (47) 
Cross 
sectional 
(n=252) 
USA Explore association between cognitive 
impairment and type 2 diabetes, 
health-related behaviours; health 
services utilisation. 
Self-report of 
physician diagnosis 
MMSE 
Behavioral Dyscontrol Scale (BDS)  
Oral hygiene (frequency of brushing 
and frequency of flossing) 
IADLs (total IADLs, medication, and 
meal planning) 
SAILS (incl. medication) 
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Table 2 Continued 
Authors  Study Design 
(sample size) 
Location Aim of study Diabetes diagnosis Neuropsychological tests Self-help or other health 
behaviour measures 
Gorska-
Ciebiada et 
al, 2014 (48) 
Cross 
sectional 
(n=276) 
Poland To estimate the prevalence of 
cognitive impairment, depressive 
mood, and its comorbidities and risk 
factors 
Record Review or 
physician 
Montreal Cognitive Assessment 
(MoCA) Geriatric Depression Scale 
(GDS-30)   
Katz Basic Activities of Daily living 
(BADL) 
Lawton Instrumental Activities of 
Daily Living (IADL) 
Koekkoek et 
al, 2015 (49) 
Cross 
sectional 
(n=225) 
Netherlands Explore differences in health status 
and depressive symptoms between 
patients with type 2 diabetes with and 
without undiagnosed cognitive 
impairment. 
Record Review or 
physician 
Test Your Memory (TYM) Self-
Administered Gerocognitive 
Examination(SAGE)  
MMSE 
Short Form-36 (SF-36) 
EQ-5D  
EuroQol Visual Analogue Scale 
(EQ-VAS) 
Jagielski et 
al, 2015 (50) 
Cross 
sectional 
(n=27 271) 
China Explore association between type 2 
diabetes and cognitive impairment  
Self-report of 
physician diagnosis, 
measured fasting 
blood glucose (FBG) 
MMSE 
Delayed Word Recall Test (DWRT)  
Self-rated health status  
Bruce et al 
2009 (51) 
Cohort 
(n=302) 
Australia Explore associations between 
hypoglycaemia and cognitive status 
Laboratory 
(HbA1c) 
MMSE Hypoglyaemic episodes (self-report, 
medical record review, linkage to 
health service data) 
Verny et al 
2015 (52) 
Cohort 
(n=987) 
France Study factors associated with cognitive 
decline in adults with type 2 diabetes 
Record Review or 
physician 
Global function ADLS, IADLS 
Demakakos 
et al, 2017 
(53) 
Cohort 
(n=10 524) 
UK Associations between baseline 
diabetes and elevated depressive 
symptoms and trajectories of cognitive 
function over a 10-year follow-up. 
Self-report, 
laboratory measures 
biennially  
(HbA1c) 
Semantic verbal fluency test 
10-word immediate and delayed 
recall test 
ADLS 
 
Table 3 Characteristics of interventional studies included in this review 
Authors  Study Design Location Aim of study Diabetes diagnosis Neuropsychological tests Self-help or other health 
behaviour measures 
Punthakee 
et al, 2012 
(54) 
RCT 
(n=2 956) 
USA, 
Canada 
To assess the effect of baseline 
cognitive function on subsequent risk 
of severe hypoglycaemia, and risk for 
severe hypoglycaemia, and whether 
intensive versus standard glycaemic 
control strategies affect these 
relationships. 
Laboratory MMSE 
DSST 
4 questions on ability to manage 
diabetes 
RAVLT 
Stroop test 
Patient Health Questionnaire (PHQ) 
Hypoglycaemia severe enough to 
require medical assistance by self-
report 
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Few studies reported on motor function. Commonly reported tests and their associated effect 
size measured using Cohen’s delta are shown in table 5. The effect size for most tests was 
small to moderate. The individual tests with the largest effect size were the Grooved Peg 
Board (both hands), Trail Making Test B, RAVLT (immediate), and the delayed Rey 
Osterrieth Complex Figure. None of the studies included in this review used the Groove Peg 
Board or the Rey Osterrith Complex Figure tests and only Kazlauskaite et al and Munshi et 
al used Trail Making Tests.(42,46) 
 
Table 4 Selected participant characteristics of included studies 
Authors Age 
(years,S
D) 
Sex 
(% 
Female) 
Level of education 
(Years, SD or %) 
Ethnicity  
(%, Reported) 
Measure of 
glycaemia 
(% HbA1c, SD or 
as reported] 
Sinclair et al, 
2000 (41) 
74.9 (7) 96 65% (schooled to 14) 
Not adequately 
reported (NAR) 
7.8 (3)2 
Kazlauskaite et 
al, 2009 (42) 
56 (11) 63 
40% High school or 
less 
60% Black African 
American 
8 [6.1 – 116.6] 
Primozic et al, 
2010 (43) 
63.7 (9.9) 51 11.2 years 91% Slovene  7.7 (1.3) 
Rodríguez-
Pascual et al, 
2011 (44) 
81.4 (5.7) 70 
85% Primary school 
only 
NAR 7.4 
Feil et al, 2012 
(45) 
70 (7.4) 53 
33% less than high 
school 
79% White 7.2 (2.5)1 
Munshi et al 
2012 (46) 
77 (5) 52 15 years (3) NAR 7.3 (1.2) 
Tran et al, 2014 
(47) 
71.8 (6.7) 59 10.3 years (3.5) 64% Hispanic NA 
Gorska-Ciebiada 
et al, 2014 (48) 
73.6 (4.8) 54 11.3 years (2.4) NAR 7.2 (0.7) 
Koekkoek et al, 
2015 (49) 
76.8 (5) 40 NAR NAR 7 (3) 
Jagielski et al, 
2015 (50) 
61 (6.9) 72 
40% Primary school 
or less 
NAR 5.2 (2.6)1 
Bruce et al 2009 
(51) 
76 (6)1 52 NAR NAR 71 
Verny et al 2015 
(52) 
77 (5.7)1 52 
55% Less than high 
school 
NAR 7.6 (1.3)1 
Demakakos et al, 
2017 (53) 
65 (9.9) 47 38% no qualifications NAR NA 
Punthakee et al, 
2012 (54) 
62.5 (5.8) 47 
39% High school or 
less 
70% Non-Hispanic 
white 
8.3 (1.0) 
 
Self-management and health care behaviours 
Studies also reported a variety of self-care or health behaviours. (See table 1.) Most studies 
measured either Activities of Daily Living (ADLS) or Instrumental Activities of Daily Living 
(IADLS). (41,44,46–48,52,53) Studies also reported blood glucose measuring, oral health, 
falls, and hypoglycaemia which may be important individual aspects of self-care in people 
with type 2 diabetes. (42,46,47,51,54) Three of the included studies measured a more 
                                                          
2 Calculated from published data 
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comprehensive set of diabetes specific behaviours; taking diabetes medication, exercising 
regularly;, following a recommended eating plan, checking blood glucose level, and checking 
feet for wounds or sores. (43,45,46) Feil et al reported individual scores whereas the other 
two reported composite scores in their models and it was not possible to explore whether 
one or more diabetes specific behaviours was associated with a measure of cognitive 
function. 
Table 5 Cognitive domains most commonly thought to be being tested by specific 
named tests adapted from Palta et al. (14)  
Cognitive domain Test or instrument Pooled Cohen’s d 
effect size from Palta 
et al. (14) 
Verbal memory Rey Auditory Veral Learning 
Test (RAVLT) – Immediate 
Immediate -0.40 (-0.53 to -0.28) 
Delayed -0.33 (-0.47 to-0.19) 
Wechsler Memory Scale 
(WMS), Logical Memory 
Immediate -0.13 (-0.55 to 0.30) 
Delayed -0.18 (-0.66 to 0.30) 
California Verbal Learning 
Test (CVLT) 
Immediate -0.19 (-0.49 to 0.12) 
Delayed -0.27 (-0.45 to -0.09) 
Visual memory Rey Osterrieth Complex 
Figure 
Immediate -0.33 (-0.52 to -0.15) 
Delayed -0.38 (-0.54 to -0.21) 
WMS-Visual Reproduction Immediate -0.18 (-0.55 to 0.20) 
Delayed -0.11 (-0.38 to 0.15) 
Attention/Concentration Weschler Adult Intelligence 
Scale (WAIS)  
Forward -0.18 (-0.27 to -0.08) 
Backward -0.12 (-0.22 to -0.02) 
Stroop  Part I -0.28 (-0.45 to -0.11) 
Part II -0.26 (-0.42 to -0.10) 
Processing speed WAIS DSST -0.33 (-0.45 to -0.20) 
Trail Making Test  A -0.34 (-0.44 to -0.24) 
Executive function Trail Making Test  B -0.39 (-0.52 to -0.27) 
Stroop Part III -0.26 (-0.39 to -0.12) 
Wisconsin Card Sorting Test Categories -0.35 (-0.70 to 0.00) 
Motor function Grooved peg board Dominant hand -0.60 (-0.90 to -0.31) 
Non-dominant hand -0.51 (-0.81 to -0.22) 
Finger tapping Dominant hand -0.17 (-0.32 to -0.02) 
Non-dominant hand -0.23 (-0.39 to -0.08) 
 
Association between type 2 diabetes and cognitive impairment 
Four of the included studies included a comparison population without type 2 diabetes. 
(41,47,50,53) Reported findings from both the cross-sectional GBC study and the three cohort 
studies showed that adults with type 2 diabetes performed worse on global and individual 
neuropsychological tests than adults without type 2 diabetes. All models were adjusted for 
age, sex, education, depression score as well as other potential confounders. 
In studies with only participants with type 2 diabetes Feil et al, Koekoek et al, and Primozic 
et al  did not find evidence that HbA1c or duration of disease was significantly associated 
with cognitive impairment. (45,49) In contrast, Kazlauskaite et al, and Gorska-Ciebiaa et al, 
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showed that HbA1c and duration of disease were significantly associated with cognitive 
impairment. (42,48) The effect sizes were small. Reviewing the findings for associations 
between type of blood glucose lowering treatment were similarly mixed; some but not all 
studies showed that insulin containing regimens were associated with worse performance on 
neuropsychological tests. Some but not all the studies found that people with both type 2 
diabetes and symptoms of depression had lower neuropsychological test and self-care 
scores. 
Association between cognitive impairment and self-care 
We used the Capability Opportunity Motivation – Behaviour (COM-B) model for 
characterising and changing behaviours to develop a theoretical model of how cognitive 
function and dysglycaemia in type 2 diabetes  interact with self-management activities. (60) 
This model is slightly different to the one suggested by Feil et al (45) – it doesn’t conceive of 
the relationship as cyclical i.e. poor glycaemic control leads to poor cognitive function leads 
to poor self-care which exacerbates poor control etc. Rather, it highlights the mediating role 
that an individual’s capability (physical and psychological), motivation (autonomic and 
reflexive), and opportunity (social and physical) may play in the relationship and the 
bidirectional relationship of the interactions.  
 
 
Figure 3 Hypothesised model characterising the relationship between type 2 diabetes, 
cognitive function and self-management activities using the COM-B model. 
All the studies included in this review found an association with some if not all their reported 
measures of self-care. For example, Feil et al (45) sampled adults in the community and 
found that the percentage of participants who reported being able to adhere to each 
diabetes related self-care task decreased with worse neuropsychological test scores; the 
self-care tasks most likely to be affected were following a recommended eating plan and 
participating in regular physical activity. Results in Tran et al also showed worse test scores 
to be associated with decrease in self-reported meal, medication management, and activities 
of daily living scores. (47) Meal planning and preparation is a complex often social activity 
where aspects of opportunity (for example whether a person is living independently or in a 
care facility), motivation (for example finding and selecting healthful ingredients), and 
capability (for example negotiating meal selection with partners or family) dynamically 
interact with cognitive function and self-management activities. (61)  
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Discussion 
In this structured review of literature on the relationship between cognitive function and 
impairment on self-care and related health behaviours in adults with type 2 diabetes mellitus 
we found evidence that type 2 diabetes is associated with cognitive impairment and with 
measures of self-management. There is evidence that people with type 2 diabetes have 
worse cognitive function than those without and that those with impaired cognitive function 
have evidence of poorer self-management. These findings are similar to those reported in a  
recent small systematic review. (39) 
We have proposed a model to potentially explain how type 2 diabetes dysglycaemia, 
cognitive function, and self-management synergistically act on each other through mediators 
of capability, motivation, and opportunity. We think it is plausible that the relationship is 
dynamic and shifts over time. This model also allows for multi-morbidity to be accounted for 
(again through capability, motivation, and opportunity as mediators.) 
Of concern is that none of the trials to date have showed benefit of glycaemic control in 
preventing or treating cognitive decline associated with type 2 diabetes. (31) This may 
suggest that targeting other aspects of the relationship are required to improve outcomes in 
this group. For example, providing additional treatment adherence support to people with 
cognitive impairment (with special focus on supporting eating as recommended and being 
physically active.) 
This review has several limitations to be noted. We found few studies explicitly tying the 
outcomes of neuropsychological tests to important clinical and health behaviours. Of the 
studies included none were from low or middle-income settings and none were from Africa. 
We found two studies exploring the association between type 2 diabetes and cognitive 
function in hospital outpatient populations. (62,63) Results from both studies showed 
cognitive impairment to be common in these populations. It is likely that the associations 
noted between impaired cognition and poorer self-care in this review may be found in these 
populations as well.  
The studies included reported a wide variety in how people with type 2 diabetes were 
identified (self-report, medical record review, biochemical measurements), how cognitive 
function was measured (global or specific domains measured, face-to-face interview or 
telephone interview) and scored (raw or transformed), and which confounders were 
measured and adjusted for in models. This variety made it difficult to directly compare results 
across studies. Also, most of the studies included in this review were cross-sectional which 
limits inferences on the role of chronic hyperglycaemia as well whether cognitive impairment 
is static or dynamic over time; and whether shifts in cognitive impairment vary across 
domains.   
While there is a growing body of epidemiological evidence of the association between type 2 
diabetes and cognitive impairment in diverse study populations there is much less published 
evidence on the clinical relevance of small to moderate differences in neuropsychological 
test scores. Researchers could meaningfully focus on standardising the neuropsychological 
tests used to measure cognitive function in people with type 2 diabetes (specific attention 
should be given to measuring those domains thought to be important based on known 
pathophysiology) and on standardising the self-management measures of importance. 
Attention should also be given to conducting research in settings where type 2 diabetes is 
highly prevalent as it is in many low and middle-income settings. Lastly, there is probably 
sufficient evidence of an association between cognitive impairment and self-management in 
adults with type 2 diabetes to warrant intervention studies focused on behavioural and 
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complex interventions beyond glycaemic control and which are suitable for implementation in 
low and middle-income settings.    
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Appendix 2. List of Cognitive Measures adapted from NHI Healthy Brain 
Project (64) 
Learning and memory 
Verbal learning and memory Nonverbal learning and memory  
Wechsler Memory Scale - Revised (WMS-R)  
Selective Reminding Test (SRT)  
Cued Selective Reminding Test  
Fuld Object Memory Test  
Rey Auditory Verbal Learning Test (AVLT)  
California Verbal Learning Test (CVLT)  
Delayed Word Recall Test  
New York University Memory Test  
Rivermead Behavioral Memory Test 
Visual Reproduction subscale of Wechsler Memory 
Scale - Revised  
Benton Visual Retention Test (VRT)  
Benton Visual Retention Test, Multiple Choice (VRT-
MC)  
Rey-Osterrieth Complex Figure Test  
Delayed Recognition Span Test (DRST)  
 
Executive function abilities3 Language 
Trail Making Test (TMT)  
Ravens Progressive Matrices  
Wisconsin Card Sorting Test / Modified Wisconsin 
Card Sorting Test  
Stroop Color-Word Interference Test  
Visual-Verbal Test  
WAIS-R Similarities subtest  
Gorham Proverb Interpretation Test 
Aphasia screening battery  
Halstead-Wepman Aphasia Screening Test  
Confrontation naming  
Boston Naming Test  
Verbal fluency  
Controlled Oral Word Association Test (FAS)  
Isaacs Set Test (IST)  
Comprehensive batteries to assess linguistic skill  
Boston Diagnostic Aphasia Examination (BDAE)  
Multilingual Aphasia Examination (MAE) 
 
Visuospatial abilities Sustained Attention 
WAIS-R Performance subtests  
Clock Drawing Task  
Figure copying  
Figure matching 
Digit Span from WAIS-R  
Mental Control subtest from WMS-R  
Attention/Concentration Index from WMS-R  
Continuous Performance Test (CPT)  
The "A" Test 
 
Brief mental status tests Intelligence Tests 
Short Portable Mental Status Questionnaire (SPMSQ)  
Mini-Mental State Exam (MMSE)  
Modified Mini-Mental State Exam (3MS)  
Cognitive Abilities Screening Test (CASI)  
East Boston Memory Test (EBMT)  
Blessed Information, Memory, Information and 
Concentration Test (BIMC)  
Neurobehavioral Cognitive Status Examination 
(NSCE)  
7 Minute Screen  
Geriatric Mental State Examination  
Telephone Interview for Cognitive Status (TICS) 
Wechsler Adult Intelligence Scale - Revised  
(WAIS-R)  
National Adult Reading Test (NART)  
Primary Mental Abilities 
 
 
 
 
 
 
 
  
                                                          
3 concept formation, abstraction, set shifting, set maintenance, planning, self-monitoring, 
divided attention 
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Background: Type 2 diabetes has been found to be associated with cognitive impairments in 
planning, problem solving, organization, and working memory and also with an increased risk of 
dementia. Neurocognitive impairment may impact self-care and other health behaviours increasing 
the risk of poor health outcomes in this patient population. Detection of neurocognitive impairment in 
low and middle-income settings is challenging; there is a lack of validated screening tools suitable 
for local use in primary care and outpatient settings and access to formal neuropsychological testing 
services is limited. The inability to easily identify people with type 2 diabetes with neurocognitive 
impairments is constraining the development of context appropriate interventions to improve the 
care and outcomes in this sub-group of patients.  
Aim: The aim of the current analysis is to explore associations between neurocognitive function and 
measures of diabetes control (HbA1c, disease duration, type of blood glucose lowering treatment) at 
baseline in a population of people with type 2 diabetes participating in a clinical trial of treatment 
adherence support using SMS-text messages. 
 
Materials and Methods: SMS supporting treatment Adherence foR for type 2 Diabetes (StAR2D) is 
a randomised clinical trial testing if a system of SMS-text messages to support treatment adherence 
is more effective than usual care for controlling blood sugar among people with type 2 diabetes in 
sub-Sahara Africa (ISRCTN70768808). We have embedded neurocognitive assessment sub-
studies into the Cape Town trial site. At baseline participants in the StAR2D trial complete a novel 
mobile-device based cognitive assessment, NeuroScreen, assisted by a field research assistant. 
The assessment contains 9 variants of tests found in the gold-standard neuropsychological test 
battery that have been adapted and normed for use in South Africa. It is available in English or 
isiXhosa. The assessment takes between 20 to 40 minutes depending on participant error rate. This 
cross-sectional analysis of baseline data uses linear and logistic regression models to explore 
associations between neurocognitive function and measures of diabetes control. 
 
Results: Six hundred participants eligible for enrolment in the StAR2D trial were recruited from the 
Cape Town trial site; 499 participants completed the baseline neurocognitive screening assessment 
(20 to 40 minutes to complete); 101 participants did not complete the assessment (commonly due to 
eyesight, hearing or motor difficulties e.g. hemiplegia due to previous stroke or technical difficulties.) 
We found differences in the scores in some but not all the neuropsychological tests. Using cut 
points suggested by an earlier validation study of NeuroScreen tool more than half of study 
participants would be scored as having at least mild neurocognitive impairment. HbA1c, duration of 
disease, type of blood glucose lowering treatment were not significantly associated with individual or 
overall neuropsychological test scores or odds of neurocognitive impairment. 
 
Conclusions: The prevalence of neurocognitive impairment may be substantial in this patient 
population. A novel tablet based neurocognitive screening tool was broadly feasible and acceptable 
to lay researchers and trial participants. There was no evidence that HbA1c, duration of disease, or 
type of blood glucose lowering treatment (oral agents alone or insulin containing regimens) was 
significantly associated with individual or overall neuropsychological test scores or odds of 
neurocognitive impairment. Validating this tool for this patient population and optimising its role in 
routine clinical care need further study. 
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Introduction 
Type 2 diabetes  (T2DM) is major global public health concern. (2) Low- and middle-income 
countries are disproportionally affected by the substantial and growing burden of premature 
morbidity and mortality associated with chronically elevated blood glucose levels. (3,4)  For 
example, in South Africa the estimated prevalence of type 2 diabetes is about 9%; the 
condition is also a top 10 cause of premature mortality and morbidity. (5,6) 
A key component of health care for people with diabetes is self-care and management. (6) 
Most people with type 2 diabetes will require the use of one of more blood glucose lowering 
agent in addition to a package of lifestyle modifications across many domains which often 
require ongoing negotiation in their daily lives. Planning, problem solving, organization, and 
working memory are just some of the higher order cognitive functions required for adequate 
self-care. (7) Self-care activities have been shown to be associated with improved treatment 
adherence, blood glucose control, and disease outcomes in people with type 2 diabetes. (8)  
Type 2 diabetes is a progressive multi-system disease. Type 2 diabetes has been found to 
be associated with cognitive impairments in planning, problem solving, organization, and 
working memory and also with an increased risk of dementia in populations in several high-
income settings. (65) There is less published evidence on the burden or severity of 
neurocognitive impairment in adults with type 2 diabetes in low and middle-income settings. 
Studies from Nigeria and China suggest cognitive impairment in people with type 2 diabetes 
may be very common in clinical and community settings (40% and 60% respectively.) (66,67) 
Vascular, metabolic, and neuroendocrine, chronic immune activation and inflammation are 
some of the factors that been shown to contribute to the risk neurocognitive impairment and 
dementia in people with type 2 diabetes. (14) Neurocognitive impairment may impact self-
care and other health behaviours increasing the risk of poor health outcomes in this patient 
population.(68–72) 
Currently the detection of neurocognitive impairment (NCI) in low and middle-income 
settings is challenging; there is a lack of validated screening tools suitable for local use in 
primary care and outpatient settings, and access to formal neuropsychological testing 
services is limited. The inability to easily identify people with type 2 diabetes with 
neurocognitive impairments is constraining the development of context appropriate 
interventions to improve the care and outcomes in this sub-group of patients.  
The SMS supporting treatment Adherence foR for type 2 Diabetes (StAR2D) is a 
randomised clinical trial testing if a system of SMS-text messages to support treatment 
adherence is more effective than usual care for controlling blood sugar among people with 
type 2 diabetes in sub-Sahara Africa (ISRCTN70768808). We have embedded a set of sub-
studies into the Cape Town, South Africa site of the trial which aim to improve the 
assessment of neurocognitive function in people with type 2 diabetes at wide scale in low 
resource settings using a novel mobile-device based cognitive screening tool, NeuroScreen, 
for use in this patient population. NeuroScreen is a cogntive assessment tool developed for 
use by lay health care workers in low- and middle-income (LMIC) settings. (1) 
Using data from the baseline assessment we report here on the associations between 
neurocognitive function measured using the screening tool and selected disease 
characteristics (HbA1c, disease duration, and type of blood glucose lowering treatment) 
adjusting for important potential confounders. 
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Materials and methods 
Setting and participants 
Participants for the NeuroScreen sub-study were recruited from the Cape Town site of the 
StAR2D trial; Participants were eligible for inclusion in the main trial if they were (1) adults (≥ 
18 years) and (2) willing and able to give informed consent for participation in the study, (3) 
able to communicate in one of the predominant indigenous African languages in the Western 
Cape province (e.g. English, Afrikaans Xhosa), (4) had previously been diagnosed with type 
2 diabetes by a health care worker and (5) were taking oral glucose lowering treatment 
(could also be taking insulin), (6) had access to a mobile phone and knows how to use SMS 
(help to send or receive messages allowed), and (7) was currently living in the community 
served by the clinic and planned to live there for the next 18 months. Participants were 
excluded if they had (1) a recent hospital admission for hyperglycaemia or hypoglycaemia 
(within three months), (2) were currently pregnant or within three months post-partum by 
self-report or with plans to become pregnant in the next 12-months, (3) self-reported a 
terminal medical condition. Participants were also excluded if (4) another member of their 
household was already participating or (5) if they had participated in the formative work to 
develop the trial intervention.  
Study design 
This is a cross-sectional study of associations between cognitive function and type 2 
diabetes disease characteristics at baseline. Cognitive function measured using 
NeuroScreen a mobile-device (tablet) based neurocognitive screening tool that assesses 
individuals across cognitive domains sensitive to NCI associated with type 2 diabetes (novel 
variants of 10 research validated neuropsychological tests that have been adapted and 
normed for use in South Africa.) (1) 
Procedures 
Recruitment 
The NeuroScreen questionnaire was administered as part of the baseline assessment for all 
StAR2D trial participants recruited at the Cape Town site unless a participant opted out of 
the assessment. 
Informed consent 
People interested and eligible provided written informed consent to participate in the parent 
study (StAR2D) which included completing baseline and follow-up NeuroScreen 
questionnaires. Participant information leaflets and informed consent procedures conformed 
to the Helsinki Declaration and the University of Cape Town Human subjects Research 
Ethics Committee requirements. Participants could decline completing the NeuroScreen 
assessment (i.e. opt out) without affecting their participation in the parent trial or access to 
any routine clinical care. 
Study procedures 
NeuroScreen was administered by a trained research assistant as part of the baseline 
assessment for the parent study. See Multimedia Appendix 15 in Robbins et al, A Mobile App 
to Screen for Neurocognitive Impairment: Preliminary Validation of NeuroScreen Among 
HIV-Infected South African Adults for a complete description of each test used in the 
assessment. (1)  
                                                          
5 For ease of reference this has been included in Part D as Appendix 5. 
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Measures 
Data collection 
Trained research assistants  used a modified from the questionnaire (used previously and 
harmonised with data collection tools from other GACD funded projects on diabetes mellitus) 
(73,74) to collected information on sociodemographic factors (education, employment and 
finances), medical history (previous clinician diagnoses of hypertension, cardiovascular 
disease, depression, HIV, and other chronic illnesses), current medication (for diabetes, 
hypertension and other chronic illnesses), medication adherence (5-item Medication 
Adherence Report Scale, MARS-5),(75) lifestyle (physical activity, diet, alcohol consumption 
and smoking), and health status (EuroQol Group 5-Dimension Self-Report 
Questionnaire,EQ-5D),(76) and satisfaction with treatment and care. Questionnaires were 
available in English, isiXhosa and Afrikaans. 
Anthropometry and blood pressures were measured using standardised procedures. A 
venepuncture sample was collected at the study site by a trained research nurse for 
measurement of HbA1c.  The blood samples were transported on the same day to a clinical 
trials laboratory for processing using an immunoassay on the Roche cobas c501 (Tina-quant 
HbA1c Gen. 2, Roche Diagnostics, Indianapolis, IN, USA). The laboratory participated in 
internal quality control (exchanging samples between sites for repeat testing) and external 
quality control processes.  
The NeuroScreen assessment consists of 10 tests to briefly assess across six 
neuropsychological domains: learning (two trials, five words), memory (5-minute delayed 
recall), processing speed (two Trail Making Test sequences, two visual discrimination tasks, 
and a number input task), attention (Number Span forward and backward), executive 
function (alternating trail making test sequence), and motor function (Finger-Tapping task.) 
(65) See Appendix 1 for a complete description of each test.(77) The interviewer is required 
to read standardized test instructions or play videos that provide audio-visual instructions, is 
prompted at appropriate points to offer practice trials on selected tests and is prompted to 
move on to the next test, thus sequencing through all the tests. NeuroScreen was 
administered in English or isiXhosa by trained research assistants using Android tablet 
devices.  
Definitions 
We calculated disease duration from self-reported time lived with type 2 diabetes in years 
and months; we grouped this into less than 5 years, between 5 and 10 years, and 10 or 
more year. We categorised diabetes control using measured HbA1c (%) level into tertiles; 
reasonable (mean 6.72%, 95% CI 5.4% to 7.8%), average (8.98, 8.1 to 10.0), poor 
(11.74,10.3 to 14.) We collected information on the type of diabetes medication prescribed 
from participants clinic prescribing records. We grouped these into oral medications 
(metformin, glibenclamide, gliclazide), insulin (actrapid, actraphane, protaphane), or both. 
We also collected information on use of anti-hypertensive agents and statins. 
We defined overweight as BMI of 25·0–29·9 kg/m2 and obesity as BMI of 30·0 kg/m2 or 
more. Multimorbidity was defined as the presence of diabetes mellitus plus either 
hypertension or obesity (not including overweight.)  We defined hypertension as systolic 
blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or 
current antihypertensive medication use. Education was calculated from the total number of 
years participants reported they spent in school or full-time study.  
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Data management 
All participant trial data were captured at the study site and uploaded to OpenMRS 
(OpenMRS version 1.6.1, OpenMRS Limited, Michigan) using Sana Mobile (Sana, MIT, 
Massachusetts), an open-source Android platform. NeuroScreen data were uploaded to a 
secure server and stored in a study specific data base. Data from the parent study and the 
sub-study were linked using study specific identifiers. 
Statistical analysis 
The main outcome for this cross-sectional baseline analysis is neurocognitive function. We 
summarised global neurocognitive function using two composite z-scores: (1) sum of all 
individual test scores and total errors from the trail making and number speed tests (z-score 
I), and (2) sum of four tests (Visual Discrimination 1 and 2, Trail Making 1, and Number Span 
total; z-score II). All raw scores were converted to z scores using the entire sample and 
timed tests were reverse scored so that higher scores indicated better performance. We 
defined neurocognitive impairment using 2 cut points suggested by an earlier validation 
study of NeuroScreen tool in a group of 102 HIV-positive black South African adults aged 18 
to 56 years.(1) Two cut points were used: 0.216 and 0.187. We compared the z-scores of 
individual tests between groups with and without impairment as defined using the cut-points 
above. (1) 
The main exposure variables were percentage HbA1c treated as a continuous variable, 
duration of diagnosis of type 2 diabetes (continuous), and type of blood glucose lowering 
medication (categorical variable). Type 2 diabetes is a progressive disease and HbA1c will 
tend to increase with longer duration of disease, the type of medication regimen selected is 
also related to HbA1c and indirectly to duration of disease and other patient level factors (for 
example, metformin is not used in the presence of renal impairment which is a complication 
that is more common with longer disease duration and higher HbA1c levels.) The 
relationship between duration of diagnosis of type 2 diabetes, medication regimen and 
HbA1c was explored. Student t-tests were used to explore associations between these and 
the exposure and outcome variables. χ2 likelihood ratio tests were used to assess 
heterogeneity by disease duration and medication regimen, and, where observed we present 
stratified analyses.  
The following potential confounders were included in statistical models for the main 
analyses: age, sex, years of formal education, systolic and diastolic blood pressures 
(mmHg), and blood total and HDL cholesterol levels (mmol/l); all treated as continuous 
variables. 
Data were explored visually and with Shapiro-Wilk tests to check underlying distribution 
assumptions. Univariate and bivariate analyses of the outcome and exposure variables were 
performed using two-by-two tables and t-tests. Linear regression was used to estimate the 
mean change in global neurocognitive score associated with increasing HbA1c (%) with 
                                                          
6 In the validation study the AUC for a cut point of 0.21 was 86 (95% CI 0.78-0.94 ) and the Youden 
index maximal sensitivity was 81.48% (95% CI 61.92%-93.70%) and specificity was 81.33% (95% CI 
70.67%-89.40%). The PPV was 61.11% and the NPV was 92.42%.) 
7 In the validation study the AUC for  cut point of 0.18 was 0.87 (95% CI 0.80-0.94) and the Youden 
index NeuroScreen predicted NCI cut-score of 0.18 maximized sensitivity at 92.59% (95% CI 75.71%-
99.09%) and specificity at 70.67% (95% CI 59.02%-80.62%). The PPV was 53.19% and the NPV was 
96.36%.  
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adjustment for all the factors listed above.   T-tests and logistic regression analyses were 
used to estimate the odds ratios of neurocognitive impairment defined using the two global 
summary tests (z-score I and z-score II) and cut points described above associated with 
change in HbA1c (%) adjustment for all the factors listed above. All analyses were done in 
STATA SE version 14.2 for Windows (Stata Corp, 2018). P values were two sided and 
p<0.05 was regarded as significant. 
Role of funding 
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.  
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Results 
Participant characteristics 
Six hundred participants enrolled in the parent study between November 8, 2016 and 
August 5, 2017 were assessed for enrolment in the sub-study, of whom 499 (83%) 
completed a baseline NeuroScreen assessment and were eligible for this analysis (see 
Figure 3 for a flow diagram of participants and reasons for drop out of 101 participants.) 
Assessment of neurocognitive function using NeuroScreen as part of trial enrolment 
procedures was broadly feasible and acceptable to lay researchers and trial participants. 
Most commonly trial participants were unable to complete the baseline assessment because 
of sensory (uncorrected sight or hearing difficulties) or motor (hemiplegia as a result of 
previous stroke) difficulty (48% of exclusions, 8% of total assessments.) Technical problems 
(device freezing or data transfer problems) resulted in missing data or incomplete 
assessments at a rate of about 7% of total assessments. These data were excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Flow diagram of participants recruited from StAR2D parent trial and enrolled 
into the NeuroScreen sub-studies 
Table 6 shows characteristics of study participants by sex. 76% of participants were women. 
The mean age of participants was 58.5 (SD 11.7) years. The sex distribution was similar 
among participants who did not complete the baseline assessment, although they were older 
(61.3, SD 11.8 years), reported fewer years of education (7.6, SD 3.4), and had a lower BMI 
Recruited from participants 
enrolled in StAR2D (n=600) 
Completed baseline NeuroScreen 
cognitive assessment (n=499) 
Excluded (n=101) 
Language difficulties (n=3) 
Withdrew consent (n=6) 
Sensory or motor difficulties (n=48) 
Incomplete assessments (n=24) 
Technical problems (n=20) 
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(mean BMI 31.7, s.d 5.4.) There was no material difference in duration of T2DM, HbA1c 
blood pressure, or type of blood glucose lowering agents used.  
Among participants, men and women differed in mean BMI, measures of HbA1c and blood 
pressure; women had higher BMIs and higher mean HbA1C levels but lower mean blood 
pressures.  Women were more likely to be taking oral blood glucose lowering agents and 
insulin, and to have been prescribed high blood pressure lowering medications than men. 
Statin prescribing was slightly more than 80% among both. 
Table 6 Selected participant characteristics  
CHARACTERISTICS ALL FEMALE MALE 
N 499 382 117 
AGE (MEAN, SD) 58.5 (11.7) 58.5 (11.8) 58.3 (11.4) 
YEARS OF EDUCATION 
(MEAN, SD) 
8.8 (3.3) 8.9 (3.2) 8.5 (3.7) 
LANGUAGE*    
ENGLISH (N,%) 345 (69.1%) 268 (70.2%) 77 (65.8%) 
ISIXHOSA (N,%) 125 (25.0%) 91 (23.8%) 34 (29.1%) 
YEARS WITH TYPE 2 
DIABETES  
(MEAN, SD) 
8.87 (8.4) 9.06 (8.6) 8.25 (7.6) 
BODY MASS INDEX (MEAN, 
SD)≠ 
33.0 (7.6) 34.1 (7.8) 29.8 (6.1) 
SYSTOLIC BLOOD 
PRESSURE  
(MEAN, SD) 
130.2 (17.6) 129.0 (17.1) 134.3 (18.6) 
DIASTOLIC BLOOD 
PRESSURE 
76.6 (11.0) 75.0 (10.5) 81.7 (11.1) 
HBA1C (%, SD) 9.13% (2.2) 9.20% (2.3) 8.89% (2.2) 
CHOLESTEROL    
TOTAL (MEAN, SD) 4.6 (1.1) 4.7 (1.1) 4.4 (1.1) 
HDL (MEAN, SD) 1.2 (0.4) 1.2 (0.4) 1.0 (0.3) 
PRESCRIBED MEDICATIONS 
(N, %) 
   
ORAL 323 (68%) 237 (66%) 86 (77%) 
ORAL AND INSULIN 148 (31%) 123 (34%) 25 (22%) 
BLOOD PRESSURE 
MEDICATIONS 
399 (80%) 316 (83%) 83 (71%) 
STATIN 407 (81%) 312 (82%) 95 (81%) 
*Totals do not sum to 100% - 30 participants reported Afrikaans as their preferred home language; ≠ 6 people do not have BMI recorded 
because of physical problems obtaining measurements for either weight or height including being in a wheelchair 
Raw scores from selected individual tests 
Table 7 shows raw scores from individual tests included in the NeuroScreen 
assessment. Raw scores did not materially differ between men and women except for a 
small but significant difference for Finger Tapping with the non-dominant hand (results not 
shown.) Participants were able to learn 7.66 (SD 1.85) words across two learning trials 
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(same five words per trial) and recall 2.18 (SD 1.8) words after a 5-minute delay.  The mean 
total finger taps for both the dominant and nondominant hand was 363.88 (SD 114.66) taps 
across five trials. The mean total correct responses on Visual Discrimination 1 was 8.34 
(maximum 33) and 17.78 on Visual Discrimination 2 (maximum 47). Trail Making Tests were 
reverse score with slower times indicting worse performance. On average the total time 
taken to complete the assessment was 28:31 (SD 9:41) minutes although a few participants 
took substantially longer.  
Table 7 Selected raw scores from NeuroScreen 
RAW SCORES Mean (SD) Min Max 
FINGER TAPPING BOTH HANDS 363.88 (114.66) 67 723 
VISUAL DISCRIMINATION 1 TOTAL CORRECT 8.34 (4.27) 1 33 
VISUAL DISCRIMINATION 2 TOTAL CORRECT 17.78 (10.27) 1 47 
NUMBER SPAN TOTAL (FORWARD AND 
BACKWARD) 
6 (1.74) 1 11 
VERBAL LEARNING TOTAL CORRECT 7.66 (1.85) 2 10 
DELAYED VERBAL RECALL TOTAL CORRECT 2.18 (1.8) 2 5 
TRAIL MAKING 1 COMPLETION TIME (SECONDS)A -14.80 (10.36) -120.00 0 
TRAIL MAKING 2 COMPLETION TIME (SECONDS) A -34.53 (12.71) -120.00 0 
TRAIL MAKING 3 COMPLETION TIME (SECONDS) A -13.20 (4.92) -62.77 0 
NUMBER SPEED COMPLETION TIME (SECONDS) A -53.41 (25.88) -173.75 0 
FULL BATTERY COMPLETION TIME (MINUTES) 28:31 (9:41) 4:03 130:21 
aIndicates reverse scored (slower time=worse performance). 
Exploring the association between HbA1c, disease duration, and type of blood 
glucose lowering medicine on global cognitive function score 
Table 8 shows the estimated change in global cognitive function using composite z-
score I (sum of all individual test scores and total errors from the trail making and number 
speed tests) associated with HbA1c, duration of type 2 diabetes in a linear regression model. 
Univariate or unadjusted results are shown (Model A) as well as with adjustment for age, 
sex, and education (Model B.) Model C shows the results with additional adjustment for 
HbA1c, duration of diabetes diagnosis, type of blood glucose lowering medicine, blood 
pressure, blood cholesterol, and BMI (add in use of BP meds and statins).   
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In the univariate analyses, both duration of disease and type of blood glucose lowering 
medication showed small but significant changes in the composite z-score I. These 
associations were no longer significant after adjusting for age, and years of education. In the 
final model only, age and years of education had small but significant effects on the 
composite z-score I; each additional year of age decreased z-score I by -0.02 (95% CI -0.03 
to -0.01), each additional year of education increased z-score I by 0.04 (95% CI 0.01 to 
0.07.) This analysis was repeated on composite z-score II as well as individual z-scores with 
similar results. There was no evidence of interaction between HbA1c, type of blood glucose 
lowering medicines, and duration of disease (each combination individually tested using 
likelihood ratio test.) 
 
Table 8 Change in global cognitive function using composite z-score I by HbA1c, 
duration of disease, and type of blood glucose lowering medication in linear 
regression models variously adjusted 
Selected 
characteristics  
Model A 
 (unadjusted) 
Model B  
(age, sex, education) 
Model C  
(fully adjusted)* 
HbA1c (β, 95%CI) -0.03 (-0.01 to 0.07) - -0.02 (-0.03 to 0.05) -0.02 (-0.02 to 0.07) 
Duration diabetes  
(β, 95%CI) -0.02 (-0.03 to -0.01)** -0.01 (-0.03 to 0.05) -0.01 (-0.02 to 0.00) 
Type of medication  
(β, 95%CI)┘ -4.11 (-7.84 to -0.37)** -0.14 (-0.33 to 0.04) -0.17 (-0.38 to 0.05) 
*Model B plus adjustment for  HbA1c, duration of diabetes diagnosis, type of medicine, blood pressure, blood cholesterol, 
and BMI ; **P<0.05; ┘Oral agents only as reference category and compared to regimens containing insulin 
 
Nature and pattern of neurocognitive impairment in this study population 
Using a score of 0.21 as the cut point to define neurocognitive impairment 54.3% of 
participants would be classified as having impaired cognitive function using composite score 
1 and 58.5% using composite score 2. In comparison using a score of 0.18 as the cut point 
50.9% and 57.7% of participants would be classified as having impaired cognitive function 
using the respective composite scores.  
Table 9 shows the means of individual raw scores in participants with a global composite z-
score I (sum of all individual test scores and total errors from the trail making and number 
speed tests) using 0.21 as the cut point to classify individuals as impaired or not. Means 
were compared using t-test statistics. All the individual test scores except trail making 3 
completion time were significantly different between the two groups.  Participants with a 
global composite z-score I less than 0.21 had lower raw scores and longer completion times 
for the tests. The tests with the largest difference in mean scores were Finger Tapping Both 
Hands (mean difference 86.31, 95% CI 67.53 to 105.10), Number Span total forward and 
backward (-18.40, 95%CI -23.79 to13.01) Visual Discrimination 2 total correct (6.79, 95% CI 
5.08 to 8.50), Trail Making 1 (-6.14, 95% CI -9.48 to -2.81), Trail Making 2 (-4.20, 95% CI -
8.96 to 0.55 with p 0.04) and the total time to complete the assessment (4.22, 95% CI  
23:54:58 to 23:58:11.) Visual Discrimination 1 had a mean difference of 1.87 (95% CI 1.13 to 
2.60.) The mean differences in raw scores for the remaining tests was less than one. 
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Table 9 Means of raw scores in participants with a global composite z-score I of less 
than and greater than 21 with compared using t-test statistic 
NEUROSCREEN RAW SCORES < .21(Mean, SD) ≥0.21(Mean, SD) 
FINGER TAPPING BOTH HANDS* 324.4 (117.3) 410.8 (91.7) 
VISUAL DISCRIMINATION 1 TOTAL CORRECT* 7.5 (4.1) 9.4 (4.3) 
VISUAL DISCRIMINATION 2 TOTAL CORRECT* 14.7 (9.5) 21.5 (9.9) 
NUMBER SPAN TOTAL (FORWARD AND BACKWARD)* ┘ 5.9 (1.8) 6.1 (1.7) 
VERBAL LEARNING TOTAL CORRECT* 7.5 (1.9) 7.8 (1.8) 
DELAYED VERBAL RECALL TOTAL CORRECT* 1.9 (1.7) 2.5 (1.8) 
TRAIL MAKING 1 COMPLETION TIME (SECONDS) ≠* 17.2 (13.7) 23.4 (22.3) 
TRAIL MAKING 2 COMPLETION TIME (SECONDS) ≠* 37.8 (24.9) 42.0 (28.5) 
TRAIL MAKING 3 COMPLETION TIME (SECONDS) ≠  17.2 (10.1) 17.3 (14.5) 
NUMBER SPEED COMPLETION TIME (SECONDS) ≠* 75.0 (34.1) 56.6 (25.6) 
FULL BATTERY COMPLETION TIME (MINUTES) ≠* 30:15 (12:00) 25:53 (5:32) 
*T-test for difference in means <0.05; ┘Driven by difference in scores in number span backwards ≠ reverse 
scored, slower time is worse  
 
Risk factors for neurocognitive impairment in this study population 
Tables 10 shows the odds of being classified as impaired using 0.21 cut point and global 
composite z-score I associated with HbA1c, duration of disease, and type of blood glucose 
lowering medicines. Likelihood ratio tests did not show an interaction with the above 
variables for composite z-score I but did with the more limited composite z-score II.   
In these logistic regression analyses HbA1c, disease duration, and type of blood glucose 
lowering treatment did not significantly influence the odds of being classified as impaired 
using 0.21 cut point and global composite z-score I. Participant age was the only variable 
significantly associated with the odds of being classified as impaired (OR 1.04, 95%CI 1.02 
to 1.06.) Years of education was protective but not significant in this model (OR 0.95, 95%CI 
0.89 to 1.00.)  
 
 
 
 69 
 
Table 10 Odds of associated with HbA1c, duration of disease, and type of blood 
glucose lowering agents 
SELECTED 
CHARACTERISTICS 
Model A 
 (unadjusted) 
Model B  
(age, sex, 
education) 
Model C  
(fully adjusted) * 
HBA1C (OR, 95%CI) 0.95 (0.87 to 1.02) 0.98 (0.90 to 1.10) 0.95 (0.87 to 1.04) 
DURATION DIABETES  
(OR, 95%CI) 
1.04 (1.01 to 1.06) 1.02 (0.99 to 1.04) 1.02 (0.99 to 1.05) 
TYPE OF MEDICATION 
(OR, 95%CI)┘ 
1.35 (0.93 to 1.96) 1.29 (0.88 to 1.90) 1.29 (0.83 to 2.01) 
*Model B plus adjustment for  HbA1c, duration of diabetes diagnosis, type of medicine, blood pressure, blood cholesterol, 
and BMI ; **P<0.05; ┘Oral agents only as reference category and compared to regimens containing insulin 
Discussion 
Summary of findings 
In this analysis of the cognitive function of 499 adults with type 2 diabetes being managed in 
an outpatient primary care setting in a middle-income country or LMIC using a novel tablet-
based screening tool we found differences in scores in some but not all the 
neuropsychological tests. Using cut points suggested by an earlier validation study of 
NeuroScreen tool more than half of study participants would be scored as having at least 
mild neurocognitive impairment. None of the diabetes related variables explored (HbA1c, 
duration of disease, type of blood glucose lowering treatment) was significantly associated 
with individual or overall neuropsychological test scores nor odds of neurocognitive 
impairment. There was no evidence of interaction between these variables in the main 
models. 
Limitations 
It is important to note the limitations of this study and this analysis. This is a cross-sectional 
analysis of baseline characteristics for a population enrolled in a randomised clinical trial. 
The study population may not be representative of the total population with type 2 diabetes 
because of trial inclusion criteria (including being able to provide written informed consent.) 
Although the study population is quite similar in age and sex structure to that seen in primary 
care facilities it is not representative of the known age and sex distribution for prevalent type 
2 diabetes in South Africa (prevalence of type 2 diabetes is similar in men and women). 
(5,78) The number of people who were unable to complete the assessment because of either 
uncorrected sensory difficulty (poor eyesight or hearing) or motor deficit (hemiplegia) was 
larger than anticipated (8%), and is perhaps greater in the general outpatient population with 
type 2 diabetes. This is an important sub-group of patients who may be at increased risk of 
developing cognitive impairment or dementia; hearing loss is a risk factor for dementia and 
many patients with stroke suffer post-stroke decline in cognitive function. (79) It would be an 
operational challenge if screening for neurocognitive impairment became part of routine care 
to ensure that people who could not complete one type of assessment be offered another 
type. 
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Due to the timing of this analysis we had access to a limited number of key variables, 
additional socio-demographic, clinical and self-management variables will be available for 
analysis once the trial is complete (end 2018.) Although we do not expect the additional 
variables to change the results it will be important for us to review our models with additional 
adjustment for mental health status, HIV status and alcohol and tobacco use as these are 
known to be important potential confounders. It will be important to investigate the 
relationship between self-management behaviours and treatment adherence and cognitive 
function. Although we asked about current and past mental illness we did not screen for 
depression, we also did not measure blood glucose at the time of assessment though it is 
unlikely that people who were symptomatically hyper- or hypoglycaemic would have 
completed the assessment.  
The NeuroScreen tool is in process of being validated in our study population so cut points 
used in these analyses may need to be revised and the individual tests used in composite 
summary scores may change. Normative performance data are still to be established for 
various South African language groups. We did not formally assess language fluency, for 
either English or isiXhosa. Participants were asked for their language preference by the 
research assistant. NeuroScreen is not yet available in other languages commonly spoken in 
South Africa for example Afrikaans meaning that some people who may have preferred to 
take the test in Afrikaans were assessed in a language they were less familiar with. Also, 
any neurocognitive impairment we may have detected in this study may or may not be due 
to type 2 diabetes; low education, head injuries and comorbid illness are just some of the 
common factors known to cause or contribute to impaired cognitive function.  
Strengths 
Strengths of this study include the adequate sample size of adult patients being managed in 
an outpatient primary care setting (our sample size is sufficient to detect the prevalence of 
cognitive impairment as low as 26% with 80% power at 5% significance.) The study 
population is broadly representative of clinic demographics in local context. (80) Whilst there 
were sex-specific differences in individual measures, in general participants in this study 
tended to have poorly controlled blood sugar levels (mean HbA1c 9.13%, SD 2.2) and to be 
overweight or obese (mean BMI 33 kg/m2, SD 7.6.) Systolic and diastolic blood pressures 
and serum total and HDL cholesterol levels were around the treatment targets suggested by 
local guidelines.(81) (ref SEMSDA 2017.) Over two thirds of study participants were 
prescribed oral agents alone to control their blood glucose (women 66%, men 77%.) Most 
but not all participants had blood pressure lowering agents (80%) and statins (82%) as part 
of their prescribed treatment, again men and women differed with fewer men being 
prescribed blood pressure lowering agents (71% compared to 83%.) 
Another strength is the wide range of socio-demographic, clinical, health and self-
management variables being collected in the parent trial and being linked to objectively 
measured outcomes data (HbA1c, treatment adherence) which can be used in future 
analyses.  
The mobile-device based capture of data was feasible and acceptable in a general 
outpatient setting using research assistants the equivalent of lay health workers 
administering the assessment. Although some studies have reported failure rates of zero 
industry reports suggest failure rates can be as high as 27% for some Android devices. 
(82,83) We consider the technical failure rate of  about 7% acceptable for technology being 
deployed by non-technical experts and limited in-the-field technical and engineering support. 
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Other literature and findings in context 
NeuroScreen was developed to enable lay health care workers in a primary care setting to 
screen for NCI among adults with HIV. The cognitive domains thought to be particularly 
affected in HIV associated neurocognitive impairment (HAND) are broadly similar to those in 
type 2 diabetes. The tool has been validated in populations in the USA and South 
Africa.(77,1) Compared to these our study population were similarly aged to the study 
population in the USA (58.5, SD 11.7 compared to 53.4, SD 7 years) and older than the one 
in South Africa (33.3 SD 7.5.) Our study population completed fewer years of education than 
participants in these studies (8.8, SD 3.3 compared to 11.8, SD 2.4 and 11.3, SD 2.0.) Black 
African ancestry was the most common self-reported ethnicity in all three studies. 
Participants in the current study had raw scores materially different from both USA and 
South African studies for Finger Tapping both hands (about 80 fewer taps overall i.e. 
evidence of slower motor speeds) and Trail Making Trials (longer) and Visual Discrimination 
1 (4 or more.) Number Span, Delayed Verbal Recall, and Visual Discrimination 2 were 
similar to the South African study scores and either better or worse than the scores from the 
participants in the USA study. Differences in age profile and years of education may explain 
some of the differences but some may be as a result of either inflammation related to chronic 
disease processes in general (non-specific) or disease specific pathophysiology. Although 
these groups differ comparing how scores are similar or different between groups may 
provide some insight into which domains are broadly affected by many chronic disease 
processes and which may be somewhat disease specific.  
Using the cut points to compare the results of individual neuropsychological tests between 
people who performed better and worse we found the largest difference in means scores 
with finger tapping both hands, number span total, visual discrimination 2, trail making 1 and 
2. The abridged version of the score we also explored based on the South African validation 
study among adults with HIV included four tests: visual discrimination 1 and 2, trail making 1, 
and number span total. Further validation work is required to explore whether to adapt 
selected summary scores for different patient population groups. Using these cut points 
54.3% of participants would be classified as having impaired cognitive function using 
composite score 1 and 58.5% using composite score 2. This is similar to the findings from a 
small cross-sectional study among adults with type 2 diabetes attending an outpatient 
tertiary referral diabetes clinic in Cape Town, South Africa. (62) The study results showed 
evidence of impairment in executive function in 52% of participants using a short battery of 
tests (three item registration, three item delayed recall, executive clock drawing task part 1, 
verbal fluency, and numeric problem solving.) Although the researchers reported an 
association between level of glycaemic control and neuropsychological test scores it was not 
clear which confounders had been accounted for.  
Prevalence estimates for impaired neurocognitive function among adults with type 2 
diabetes vary and may depend on the age of the study population as well as the tests and 
cut points used to define impairment. For example, in a French cohort of people over the age 
of 70 years with type 2 diabetes and using the MMSE and a score of less than 24/30 to 
indicate impairment 28.8% of the study population were impaired.(84) In a cross-sectional 
study in Nigeria among a hospital outpatient diabetes clinic population also using MMSE and 
a score cut point of 24, 40% were classified as having some form of cognitive impairment; in 
this study there was a sizeable difference in the prevalence in men (48%) as compared to 
women (30%.) (67) In contrast in a population based cross-sectional study of adults (average 
age 72 year) in China 62% of those with type 2 diabetes fulfilled Petersen’s diagnostic 
standard on mild cognitive impairment.(85) 
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Some but not all studies have shown an association between HbA1c, disease duration, and 
type of blood glucose lowering treatment and scores on neuropsychological tests. In a case-
control study of 246 participants in China researchers found that longer disease duration, 
higher HbA1c, and insulin treatment were associated with worse tests results using Mini 
Mental State Exam (MMSE), trails B, digit span, and block design. (86) The GERODIAB 
cohort showed a small but significant difference in HbA1c (0.3, SD 0.1) between the 
groups.(84)  In contrast findings from another Chinese study,  a cross sectional study of 
1174 adults (average age 70.1 years, 50% women, average years of schooling 11) which 
used MMSE and the Montreal – Cognitive Assessment (MoCA) found that while in initial 
models  1% increase in HbA1c was associated with small but significant decreases in the 
scores for both tests, this association was no longer significant once models were adjusted 
for age, sex, education, duration of disease, prevalent cardiovascular disease, and alcohol 
and tobacco exposure.(85) Similarly results from baseline cognitive assessment of 
participants in the ACCORD-MIND trial using the Digit Symbol Substitution Test (DSST), 
Rey Auditory Verbal Learning Test (RAVLT), Stroop and MMSE showed that after adjusting 
for age, sex, education, depression, diabetes duration, race, and language there remained a 
small significant effect of a 1% change of HbA1c on DSST results (-0.57, -1.01 to -.012) 
only.(87) In addition a recent systematic review of the effect of the treatment of Type 2 
diabetes mellitus on the development of cognitive impairment and dementia did not find 
evidence that improving glycaemic control prevented or delayed cognitive impairment.(88)  
Taken together this evidence suggests that individual measures of HbA1c (i.e. at a single 
time point) probably have a very small association if any at all with neuropsychological test 
scores. Chronically elevated blood glucose levels may affect neuropsychological test scores, 
type 2 diabetes is progressive disease and disease duration is perhaps in part a proxy for at 
least periods of what was chronically elevated blood glucose. Results from several studies 
have shown an association between disease duration and lower neuropsychological test 
scores. (86,89,90) However, disease duration may be confounded by other factors like age at 
diagnosis and diagnostic criteria. Similarly type of blood glucose lowering therapy may also 
be a proxy measure for disease control or disease progression.  
Conclusion 
This study of a large outpatient population of adults with type 2 diabetes managed in primary 
care showed that the prevalence of neurocognitive impairment may be substantial in this 
patient population. It also showed that use of a novel tablet based neurocognitive screening 
tool was broadly feasible and acceptable to lay researchers and trial participants. There was 
no evidence that current HbA1c, duration of disease, or type of blood glucose lowering 
treatment (oral agents alone or insulin containing regimens) was significantly associated with 
individual or overall neuropsychological test scores nor odds of neurocognitive impairment. 
Validating this tool for this patient population and optimising its role in routine clinical care 
need further study.  
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Appendix 3 NeuroScreen tests from Robbins et al (77) 
 
Learning and memory 
Verbal learning and delayed memory are assessed via a 5-item word list with two learning 
trials and a 5-minute delayed recall. Words are prerecorded and played via the smartphone 
speaker. Every administration of the NeuroScreen word list is exactly the same – each word 
is spoken at a 2-second interval in a clear, enunciated male voice. After the words are 
played, the patient is asked to say the words back in any order. The test administrator, 
viewing the screen, sees buttons with the five words from the list, as well as an “other” 
button. The administrator taps the buttons that correspond to the words the patient says. In 
the case of an intrusion, the administrator taps the “other” button. Learning is scored by 
totaling the number of correctly recalled words across both learning trials. The minimum 
score is 0 and the maximum score is 10. 
The delay recall test automatically gets queued to be administered approximately 5-minutes 
after the last learning trial is completed. The time limit is approximate because if it is reached 
during another test, NeuroScreen will not interrupt the currently administered test. Rather, 
the program waits for the current test to be completed and then forces the administrator to 
complete the delayed recall trial. The administrator reads the instructions to the patient to 
say as many words that can be remembered from the list. The administrator taps the buttons 
that correspond to the words the patient says. In the case of an intrusion, the administrator 
taps the “other” button. Delayed recall is scored by totaling the number of correctly recalled 
words. The minimum score is 0 and the maximum score is 5. 
Working memory 
Working memory is assessed via a number span test (forwards and backwards). Participants 
hear pre-recorded digit strings starting with a string of 3 digits with a max of 9 digits. Each 
number of each string is spoken at a 1-second interval in a clear, enunciated male voice. If 
participants do not get the number span correct, they are given another trial of the same 
span. After two incorrect responses, the task moves on to the number span backwards 
portion. The backwards span begins with a sequence of 3 digits and has a maximum of 8. 
Like the forwards test, participants get two trials per sequence, but if they get both incorrect, 
the test ends. The test records the longest forwards and backwards span repeated and is 
scored by summing the number of digits in each of those spans. For example, if the longest 
forward span correctly repeated had 6 digits and the longest backwards span correctly 
repeated had 4 digits, the score for this test would be 10. 
Processing speed 
Processing speed is assessed by two timed visual discrimination tasks, as well as a number 
input test. The first visual discrimination task requires patients to match a target shape to its 
correct number by tapping the number on the screen. This task is similar to Digit Symbol 
Coding of the WAIS-III (Wechsler, 1997) and Symbol Digit Modalities (Smith, 1982). The 
second task requires patients to determine if one of two symbols matches an array of 
symbols and is similar to the Symbol Search subtest of the WAIS-III (Wechsler, 1997). Both 
tests lasts 45-seconds and participants receive a practice trial with feedback. The first 
discrimination task has a total of 61 items. The second discrimination task has a total of 150 
items. Each test is scored by summing the total number of correctly answered items. 
81 
On the number input test, participants see a keypad on the screen and a target number. 
They are asked to enter the target number as quickly as possible. Participants see the target 
numbers turn green as they enter the correct numbers. If an incorrect number is pressed, the 
corresponding number in the target number turns red and the participant must correct it by 
using a back button. After a target number is entered correctly, they move on to a longer 
number. The test starts with a five digit number and proceeds in one digit increments up to a 
ten digit number. Participants must complete all six trials. The smartphone records the 
completion time for each trial, as well as the number of errors made while inputting the 
number. Participants receive a practice trial to become familiar with the keypad. This test is 
scored by summing the completion times (in seconds) for each of the five trials. The 
maximum completion time allowed is 75-seconds. 
Motor speed 
Motor speed is assessed via a finger tapping test. Patients have to tap a virtual button on the 
screen as fast as they can. Each trial lasts 10-seconds. Participants have three trials with 
their dominant hands, three trials with their nondominant hands, then two more trials with the 
dominant, then nondominant hands. Handedness is entered into the patient information 
section of NeuroScreen and the patient is automatically presented with trials based on their 
handedness. This test is scored by summing the total number of taps completed by each 
hand across the 5 trials. 
Executive functioning 
Executive functioning is assessed via a trail making type test similar to the Trail Making Test 
Parts A and B (Partington & Leiter, 1949; Reitan, 1958). Trail 1 has users use their finger to 
draw a line between numbered circles (1 – 8). The smartphone automatically times how long 
it takes to complete the trial, as well as systematically records any errors. If an error is made, 
users see a pop-up screen telling them to go back to the last correct circle. The test is 
discontinued at 35-seconds with all discontinued tests recorded as the maximum completion 
time. Trail 2 requires users to draw a line between numbered and lettered circles in an 
ascending order (letter, number, letter, number, etc.) The smartphone automatically times 
how long it takes to complete, as well as records any errors. Preceding each trial, users are 
given an abbreviated practice test. Scores for this test are completion times (in seconds). 
The test is discontinued at 40-seconds with all discontinued tests recorded as the maximum 
completion time. 
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